Low-dose IL-2 reduces IL-21⁺ T cells and induces a long-lived antiinflammatory gene expression signature inversely modulated in COVID-19 patients Jia-Yuan Zhang¹, Fiona Hamey¹, Dominik Trzupek¹, Marius Mickunas², Mercede Lee¹, Leila Godfrev¹, Jennie H.M. Yang², Marcin L Pekalski¹, Jane Kennet^{3,4}, Frank Waldron-Lvnch⁵, Mark

8 L. Evans^{3,4}, Timothy I. M. Tree², Linda S. Wicker^{1†}, John A. Todd^{1†} and Ricardo C. Ferreira^{1†}

9

- 10 ¹JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human
- 11 Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre,
- 12 University of Oxford, Oxford, United Kingdom.
- 13 ²Department of Immunobiology, King's College London, School of Immunology and Microbial
- 14 Sciences, London, United Kingdom.
- 15 ³Wellcome-MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of
- 16 Cambridge, Cambridge, United Kingdom.
- ⁴National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's
- 18 Biomedical Campus, Cambridge, United Kingdom.
- 19 ⁵Vertex Pharmaceuticals, Vertex Cell & Gene Therapies, Boston, Massachusetts, United States
- 20 of America.
- 21
- 22 [†]Co-senior authors
- 23
- 24 Correspondence:
- 25 Prof. John A. Todd:
- 26 Email: john.todd@well.ox.ac.uk
- 27
- 28 Dr. Ricardo C. Ferreira:
- 29 Email: ricardo.ferreira@well.ox.ac.uk

30 Abstract

31 Despite early clinical successes, the mechanisms of action of low-dose interleukin-2 (LD-IL-2) 32 immunotherapy remain only partly understood. Here, we examined the effects of interval administration of low-dose recombinant IL-2 (iLD-IL-2) using high-resolution, single-cell 33 34 multiomics and flow cytometry. We confirmed that iLD-IL-2 selectively expands thymic-derived FOXP3⁺HELIOS⁺ Tregs and CD56^{br} NK cells, and showed that treatment reduced the frequency 35 36 of IL-21-producing CD4⁺ T cells and of two subsets of innate-like CD8⁺ T cells, mucosal-37 associated invariant T cells and $V_{\gamma 9}V_{\delta 2}$ T cells. The cellular changes induced by LD-IL-2 were 38 associated with an anti-inflammatory gene expression signature, which remains detectable in all T 39 and NK cell subsets analysed one month after treatment. The anti-inflammatory nature of this gene 40 expression signature was supported by the observation that the same genes were also modulated in COVID-19 patients, but in the opposite direction. These findings warrant continued 41 42 investigations of the potential clinical benefits of iLD-IL-2 in immunotherapy and further 43 understanding of the development of long-term sequelae in convalescent COVID-19 patients.

44

45 Introduction

46 The use of much lower doses of interleukin-2 (IL-2) than employed in cancer therapy has shown 47 clinical efficacy in a number of inflammatory and autoimmune conditions, by stimulating a subset of CD4⁺ T cells expressing high levels of the high-affinity trimeric IL-2 receptor, designated as 48 49 regulatory T cells (Tregs)¹⁻⁹. In the autoimmune disease type 1 diabetes (T1D), the genetic association with the IL-2 pathway in mice¹⁰ and in humans^{11,12}, combined with preclinical 50 51 studies^{13,14}, have provided a strong rationale for the development of low-dose (LD)-IL-2 52 immunotherapy. Safety and dose determination studies in T1D have been informative and 53 underpin future clinical trials in T1D¹⁵⁻¹⁸. We have previously conducted an adaptive single-dose 54 observational study (DILT1D), which demonstrated the sensitivity and specificity of IL-2 signalling *in vivo* and determined a dosing range of $0.2-0.47 \times 10^6$ IU/m² of recombinant IL-2 55 (aldesleukin/proleukin) to achieve Treg increases in blood in the order of 20-50% from baseline¹⁸. 56 We then performed a second study (DILfrequency)¹⁹ to determine how often to give low-dose 57 58 aldesleukin to reliably induce a steady-state Treg induction whilst maintaining the selective 59 expansion of Tregs and not effector T cells.

60

61 Here, we explored in depth the effects and pharmacodynamics of interval LD-IL-2 dosing (iLD-62 IL-2) in DILfrequency peripheral blood mononuclear cell (PBMC) samples. We employed a recently developed targeted multiomics approach, which allowed us to simultaneously quantify 63 565 mRNA transcripts and 65 surface protein targets at the single-cell level²⁰. We performed a 64 65 detailed immunophenotypic characterization of both T and NK cell compartments, with a particular emphasis on the CD4⁺ CD127^{low}CD25^{hi} T cell and CD56^{br} NK cell subsets, which have 66 been previously shown to be highly sensitive to iLD-IL-2 treatment^{18,19}. Aside from the expected 67 expansions of thymic-derived FOXP3⁺HELIOS⁺ Tregs and CD56^{br} NK cells in T1D patients, we 68 69 show that iLD-IL-2 reduces the frequency of IL-21-producing cells, a subset that has been previously implicated in the pathogenesis of $T1D^{21-23}$. The reduction of IL-21-producing cells by 70 71 iLD-IL-2 may provide therapeutic benefit in T1D since a recent clinical trial combining anti-IL-21 with liraglutide (to improve beta cell function) slowed the decline of C-peptide²⁴. Unexpectedly, 72 73 we discovered that iLD-IL-2 also induces an anti-inflammatory gene expression signature in both

- 74 T and NK cell subsets that continues to at least one month after cessation of treatment. Altered
- 75 expression of the same set of genes, but in the opposite direction, was found to be progressively
- 76 induced and sustained in COVID-19 patients, highlighting the anti-inflammatory nature of the
- prolonged iLD-IL-2-induced gene changes. Taken together, our findings indicate that iLD-IL-2
- 78 can reduce IL-21 during treatment, and induce a suite of cellular alterations that promotes the
- 79 establishment of a long-lived anti-inflammatory environment.

80

81 **Results**

Interval administration of low-dose IL-2 (iLD-IL-2) induces and maintains increased frequencies of CD4⁺ CD127^{low}CD25^{hi} T cells and CD56^{br} NK cells

84 The DIL frequency¹⁹ study established an optimal three-day aldesleukin dosing interval, with doses 85 ranging from 0.20-0.47 \times 10⁶ IU/m² (Fig. 1a). To gain further insight into the mechanism of action 86 of iLD-IL-2, we selected 18 DIL frequency participants (adults with long-standing T1D) treated 87 with this dosing regimen (Supplementary Table 1) and characterised the cellular alterations in 88 blood by polychromatic flow-cytometry (FACS). We observed a sustained increase in the frequency of CD4⁺ CD127^{low}CD25^{hi} T cells (henceforth designated as the CD4⁺ Treg gate) during 89 the dosing phase, but no alterations in the frequency of the broader CD4⁺ conventional T (Tconv) 90 91 or CD8⁺ T cell populations (**Fig. 1b,c**), including in a subset of CD45RA⁻CD62L⁻ effector memory 92 CD4⁺ T cells (T_{EM}), known to be enriched for recently activated effector T cells (Supplementary 93 Fig. 1a-c).

94 Outside the T cell compartment, iLD-IL-2 also caused sustained increased frequencies of a subset 95 of CD56^{br} NK cells (Fig. 1c). This effect was more pronounced than the increase in CD4⁺ Tregs 96 and is consistent with the relatively high affinity of the CD56^{br} NK subset for IL-2, especially when compared to the bulk NK population^{25,26}. We observed no alteration in the frequency of the 97 98 classical CD56^{dim} NK cells, which represent the majority of CD56⁺ NK cells in circulation. The 99 IL-2-induced increase in CD4⁺ Tregs and CD56^{br} NK cells was recapitulated when assessing 100 absolute numbers of cells in circulation, although their relative low abundance in blood resulted in 101 no discernible alteration in the numbers of either CD4⁺ and CD8⁺ T cells or CD56⁺ NK cells (Fig. 102 1d.e). An increase in both frequency and numbers of CD56^{br} (but not CD56^{dim}) NK cells in blood 103 was observed in all IL-2 dose groups (Supplementary Fig. 1d-f).

104

105 Investigating IL-2-induced cellular alterations in blood using single-cell multiomics

We next profiled PBMCs from 13 selected participants treated with the three-day interval dosing regimen (**Supplementary Table 1**) using a targeted single-cell multiomics approach, which

108 enables the parallel quantification of specific mRNA and cell-surface proteins (AbSeq) in each 109 cell²⁷. To increase the power of this approach to identify small, yet potentially important, changes 110 elicited by iLD-IL-2, we have adopted a cell enrichment strategy to greatly increase the numbers 111 of CD4⁺ Tregs and CD56^{br} NK cells profiled in this study. In addition, we designed a custom 112 mRNA panel of 565 oligonucleotide probes, assessed in parallel with the expression of 65 cellsurface protein targets (Supplementary Table 2)²⁰. From each participant, we selected three 113 114 longitudinal blood samples on Day 0 (baseline), Day 27 (immediately before the last IL-2 115 injection) and Day 55 (four weeks after the last IL-2 dose), respectively. We then isolated five 116 immune populations from each sample following predefined proportions: 30% CD4⁺ Tregs; 25% CD4⁺ Tconv and CD8⁺ T cells 12% CD56^{br} and 8% CD56^{dim} NK cells, which were analysed with 117 118 or without in vitro stimulation (Fig. 1f). Unsupervised clustering of the 482,531 unstimulated cells 119 passing quality control (QC) revealed a clear delineation of the sorted T and NK cell populations, 120 identifying 15 distinct functional clusters (Fig. 1g). We observed good overlap among cells from 121 each participant, with similar representation in the five sorted immune populations 122 (Supplementary Fig. 2a-c). A similar result was observed for the clustering of the 323,839 123 stimulated cells passing QC (Supplementary Fig. 2d-f), indicating minimal batch effects that are 124 usually prevalent in scRNA-seq data.

125 In the unstimulated cells, we also identified two clusters characterised by the distinct co-expression 126 of a set of canonical cell cycle genes (see Methods), including MKI67 (encoding for Ki-67), which 127 corresponded to cycling T and NK cells (Supplementary Fig. 3a). Overall, we found no evidence 128 that iLD-IL-2 was increasing the frequency of proliferating cells. Conversely, we found a reduction 129 in the frequency of proliferating CD56^{br} NK cells and CD4⁺ Tregs at Day 27 (Supplementary 130 Fig. 3b). Given the previously reported increased frequency of Ki-67⁺ Tregs and CD56^{br} NK cells 131 following LD-IL-2 treatment, we next investigated the frequency of proliferating cells by assessing 132 the intracellular expression of Ki-67 in patients treated with either single or multiple doses of LD-133 IL2. In agreement with previous observations^{4,28,29}, we found a marked increased frequency of Ki-67⁺ cells in both CD4⁺ Tregs and CD56^{br} NK cells following the first dose of IL-2 134 135 (Supplementary Fig. 3c,d). In the multiple dosing cohort, we noted that this increased frequency of Ki-67⁺ cells persisted up to Day 27 only in CD56^{br} NK, but not in the CD4⁺ Treg cells 136 (Supplementary Fig. 3d). This discrepancy between the multiomics and FACS assessment of 137 138 proliferating CD56^{br} NK cells may reflect a difference in the use of protein or mRNA markers to

139 assess cell cycle progression. Both MKI67 (mRNA) and Ki-67 protein are synthesised and 140 accumulate during the S and G2/M phases of the cell cycle and show very good correlation in 141 synchronised cells³⁰. However, in contrast to MKI67, Ki-67 protein is more long-lived, and can 142 still be detected in G1 after cell division³¹. The levels of Ki-67 protein in G1 depend on the rate of 143 protein accumulation during the S and G2/M phases, leading to the much higher rate of detection 144 of Ki-67⁺ cells compared to the frequency of cells in the S-G/M phase (eg. 37% vs 1% in Fraction 145 II Tregs)³². Consistently, we found that 20% of total CD4⁺ Tregs are Ki-67⁺ at baseline, but only 146 $\sim 1\%$ were identified as proliferating by multiomics analysis. These data indicate that in contrast to Ki-67⁺ protein levels, mRNA quantification allows a more specific identification of actively 147 148 dividing cells (in the S-G/M phases). Therefore, an explanation for the discrepancy between the 149 FACS and multiomics assessment of proliferating CD56^{br} NK cells at Day 27, is that the increased 150 levels of Ki-67⁺ cells reflect protein accumulation in recently divided G1 cells. In contrast, the 151 decrease in proliferating cells from the multionics analysis reflects a reduction of actively dividing 152 cells in blood, possibly due to an increased likelihood for cells to enter the cell cycle in tissues as 153 IL-2 accumulates on the extracellular matrix during dosing 33-36.

154 Interval administration of low-dose IL-2 selectively expands FOXP3⁺HELIOS⁺ Tregs

Next, we sought to investigate whether our iLD-IL-2 regimen altered the relative composition of 155 the cells sorted from the CD127^{low}CD25^{hi} Treg gate (Supplementary Fig. 4). Analysis of the 156 157 expression of the canonical Treg transcription factors FOXP3 and IKZF2 (encoding HELIOS) 158 allowed the stratification of CD127^{low}CD25^{hi} Treg clusters into three functional groups according 159 to their origin (Supplementary Fig. 5 and Methods). Differential abundance analysis revealed an 160 enrichment in the frequency of naïve FOXP3⁺HELIOS⁺ Tregs and a concomitant reduction of 161 CD25⁺ FOXP3⁻HELIOS⁻ Teffs on Day 27, after the conclusion of the four-week IL-2 dosing 162 phase, immediately before the last of the ten aldesleukin injections (Fig. 2a,b), which was replicated in stimulated cells (Fig. 2c,d). Given the observed increase in CD127^{low}CD25^{hi} T cells 163 164 by FACS following LD-IL-2, we next investigated whether these changes were also reflected in 165 the absolute numbers in circulation, which were inferred from the relative frequencies identified by single-cell analysis, scaled by the whole-blood CD127^{low}CD25^{hi} Treg counts. We found that 166 the IL-2 induced expansion on Day 27 was restricted to the thymic-derived FOXP3⁺HELIOS⁺ 167 168 Treg subsets (Fig. 2e). We observed very good concordance between unstimulated and stimulated

169 conditions, with naïve Tregs showing >2-fold increase and memory FOXP3⁺HELIOS⁺ Tregs 170 displaying approximately a 70% increase in cell numbers compared to baseline pre-treatment 171 levels (Fig. 2e). In contrast, despite the expansion of CD127^{low}CD25^{hi} T cells, we obtained no evidence of alterations in the number of activated CD25⁺ FOXP3⁻HELIOS⁻ Teffs contained in this 172 173 population, even though they express the high affinity trimeric IL-2 receptor (Fig. 2e). 174 Furthermore, we observed no changes in the *in vitro* suppressive capacity of CD4⁺ 175 CD127^{low}CD25^{hi} T cells after IL-2 treatment on a per cell basis compared to the pre-treatment cells 176 (Fig. 2f). The alterations in the relative composition of CD127^{low}CD25^{hi} T cells were found to be transient and reverted to baseline one month after the last dose of IL-2 (Day 55; Supplementary 177 178 Fig. 6a-d). In contrast, we observed no notable changes in the relative abundance of CD4⁺CD25⁻ ^{/low} Tconv subsets during or after IL-2 treatment (Supplementary Fig. 7). 179

180 Using pseudo-time analysis, we identified a single trajectory of FOXP3⁺ Treg differentiation 181 among CD4⁺ T cells, stemming from the conventional naïve Tregs towards the classical HLA-II⁺ 182 effector Treg subset (Supplementary Fig. 8a-c). In agreement with our compositional analysis, 183 we found a significantly increased ratio of naïve to HLA-II⁺ Tregs at Day 27 (Supplementary Fig. 8d). Notably, there was no alteration in the differentiation status of Tregs in response to iLD-184 185 IL-2, as illustrated by the overlapping pseudo-time distribution within the Treg differentiation 186 trajectory between Days 0, 27 and 55 (Supplementary Fig. 8d). These data indicate that iLD-IL-187 2 treatment is affecting only the output and/or survival of thymic-derived naïve Tregs but not their 188 differentiation towards HLA-II⁺ effector Tregs. Furthermore, we also replicated the transient IL-189 2-induced increase in the frequency of naïve Tregs by measuring the naïve:memory Treg ratio at 190 Day 27 by FACS in all 18 DIL frequency participants treated with the 3-day interval dosing 191 schedule (Supplementary Fig. 9a-c). We found good concordance between FACS and single-cell 192 data on the frequency of naïve and memory Tregs as well as their ratios (Supplementary Fig. 193 9d,e). To confirm the characterisation of Treg subsets obtained through the single-cell multiomics 194 analysis, we next assessed the protein expression of FOXP3 and HELIOS by FACS in our single 195 and multiple dosing replication cohorts. In agreement with the multiomics analysis, we found a 196 selective decrease in the relative proportion of CD45RA- FOXP3-HELIOS- cells within 197 CD127^{low}CD25^{lii} T cells in both cohorts in response to iLD-IL-2 (Supplementary Fig. 10a-c). 198 These results translated into a consistent increase in the frequency of both CD4⁺CD25^{hi} FOXP3⁺

199 Treg subsets and a concomitant reduction in CD4⁺CD25^{hi} FOXP3⁻HELIOS⁻ Teffs
200 (Supplementary Fig. 10d,e).

201 In addition to the conventional CD25^{hi} FOXP3⁺ Treg subsets, we have recently shown that a subset 202 of CD25^{-/low} FOXP3⁺ T cells are increased in patients with autoimmune diseases³⁷. We found no substantial change in the frequency of $CD25^{-/low}$ FOXP3⁺ T cells (defined as cells with >=1 copy 203 of FOXP3 within the CD4⁺CD25^{-/low} Tconv gate; Supplementary Fig. 11a,b). We replicated 204 205 these results using a FACS approach to vastly increase the number of characterised CD25^{-/low} 206 FOXP3⁺ T cells. In agreement with the multiomics analysis we found no change in the frequency 207 of this rare subset in either the single or multiple dosing cohorts (Supplementary Fig.11c-g). 208 However, we noted a small reduction in the frequency of CD25^{-/low} FOXP3⁺ T cells at Day 27 by 209 both methods, suggesting that iLD-IL-2 may restore the CD25 expression in these cells.

210

211 IL-21-producing T cells are reduced by iLD-IL-2 treatment

212 Among the identified CD25⁺ FOXP3⁻HELIOS⁻ Teff clusters within the sorted CD127^{low}CD25^{hi} 213 Treg cells, we noted an IL-2-induced reduction of a subset with a marked T follicular helper (T_{FH}) 214 cell profile, including the expression of canonical T_{FH} receptors CXCR5, PD-1 and ICOS, and the 215 transcription factor *MAF* (CD25^{hi} T_{FH}, cluster 8; Supplementary Figs. 4a and 6a). Although differentiated T_{FH} cells are rare in blood, within cells sorted from the CD25^{-/low} Tconv gate, we 216 217 were able to characterise an analogous heterogeneous cluster of central memory (T_{CM}) CXCR5⁺ 218 cells (cluster 1; Supplementary Fig. 7a-c), which is known to be enriched with circulating 219 precursors of T_{FH} cells. Upon *in vitro* stimulation, which elicited the expression of the classical 220 T_{FH} cytokine IL-21, we obtained a better discrimination of the T_{FH} clusters. This led to improved differentiation of a cluster of CXCR5⁺ T_{CM} cells (cluster 2) and a cluster of CXCR5^{low} IL-21⁺ T 221 cells (cluster 6) that was reduced with IL-2 dosing (Supplementary Fig. 7d-f). In addition, within 222 the CD127^{low}CD25^{hi} Treg gate, *in vitro* stimulation allowed the stratification of the activated 223 224 CD25⁺ T_{FH} cells into two separate clusters (cluster 10 and 11) based on their expression of IL-21 225 that were both reduced by iLD-IL-2 treatment (Supplementary Fig. 6b). We note that a related cluster of FOXP3⁺ T follicular regulatory cells (T_{FR}, cluster 11 in unstimulated cells) which, in 226 227 addition to the T_{FH} signature, also featured a distinct Treg transcriptional profile as well as the

upregulation of *POU2AF1* and *CCR9*, was not altered by iLD-IL-2 treatment (Supplementary
Fig. 6a).

230 Next, we compared the transcriptional profile of the four identified T_{FH}-like clusters marked by 231 the specific upregulation of IL-21 expression. We identified a continuum of T_{FH} cell differentiation 232 among these clusters, with the CD25⁺IL-21⁺ T_{FH} subset representing the terminal stage of 233 maturation in blood, as illustrated by their classical T_{FH} profile and increased IL-21 production 234 (Fig. 3a). Analysis of the co-expression of CXCR5 and IL-21 revealed that IL-21 was 235 preferentially expressed within the CXCR5⁺ cells (**Fig. 3b**). The exception was in the CXCR5^{low} IL-21⁺ cluster, where approximately 50% of the IL-21⁺ cells were also CXCR5^{low}. These data 236 237 suggest that our single-cell multiomics approach allows us to specifically identify the more 238 differentiated IL-21-producing T cells in this cluster, with a phenotype resembling the CXCR5^{low} 239 PD-1^{hi} circulating T peripheral helper (T_{PH}) cells that have been previously shown to be increased in T1D patients²³. Furthermore, we found similar profiles between the CXCR5⁺ T_{CM} and the 240 CD25⁺ T_{FH} clusters sorted from the CD25^{-/low} Tconv and CD25⁺ Treg gates, respectively, with the 241 242 latter likely representing an earlier stage of T_{FH}-cell differentiation. In agreement with this shared 243 identity and developmental stage, the CXCR5⁺ T_{CM} and CD25⁺ T_{FH} subsets displayed largely 244 overlapping embeddings among all stimulated CD4⁺ T cells (Fig. 3c,d). In contrast to these three 245 conventional T_{FH}-like subsets, which seem to share a similar differentiation pathway, the CXCR5^{low}IL-21⁺ CD25^{-/low} Teff cluster represented a much more heterogeneous cluster with a 246 247 scattered clustering profile and increased IL-21 production (Fig. 3c,d).

248 To better discriminate the effect of IL-2 on the differentiation of IL-21-producing cells, we then 249 stratified the cells in these four T clusters according to their expression of IL-21 to define activated 250 T_{FH} profiles (Fig. 3e). Consistent with the results from the differential abundance analysis 251 (Supplementary Figs. 6b and 7e), we found evidence for a reduction in the relative proportion of $IL-21^+$ cells at Day 27 in the two subsets with higher frequencies of $IL-21^+$ cells (Fig. 3f). 252 253 Furthermore, pseudo-time analysis in total stimulated CD4⁺ T cells revealed a similar trajectory of 254 T_{FH} cell differentiation characterised by the acquisition of an activated T_{FH} phenotype and 255 production of IL-21 (Supplementary Fig. 8e-g). In contrast with the FOXP3⁺ Treg trajectory, 256 iLD-IL-2 was found to impair this differentiation trajectory, as illustrated by the reduced pseudotime distribution at Day 27 among cells from the more differentiated CD25⁺IL-21⁺ T_{FH} subset 257

258 (Supplementary Fig. 8h). These results further support a broader, previously uncharacterized,

259 effect of iLD-IL-2 immunotherapy in potentially inhibiting the differentiation of IL-21-producing

260 cells. In addition to the reduction of IL-21-producing cells, we also obtained some evidence (FDR-

261 adjusted P = 0.096) for the reduction of another subset marked by the expression of many pro-

262 inflammatory cytokines, including GM-CSF, IL-21 and IL-2, as well as the classical type-2

263 inflammatory cytokines IL-4 and IL-13 (CD25⁺ T_{H2} T_{EM}, cluster 6; **Supplementary Figs. 4b** and

264 **6b**).

265 Effects of iLD-IL-2 on CD8⁺ T and CD56⁺ NK cells

266 In the CD8⁺ T cell compartment, differential abundance analysis revealed no discernible 267 differences in the relative composition of the conventional $\alpha\beta$ CD8⁺ T cell subsets after IL-2 268 treatment. However, we identified a previously uncharacterised reduction of two subsets of innate-269 like CD8⁺ T cells, including mucosal-associated invariant T cells (MAIT; cluster 4) and $V_{\gamma 9}V_{\delta 2}$ T cells (cluster 9; Fig. 4a,b and Supplementary Fig. 12). In contrast to the IL-2 induced alterations 270 271 in the CD4⁺ T cell compartment, the reduction of circulating MAIT and $V_{\gamma 9}V_{\delta 2}$ T cells was more 272 long-lived and there was still evidence of a reduced frequency in blood one month after the last 273 dose of IL-2 (Fig. 4c).

274 Finally, in the CD56⁺ NK cell compartment, despite the lower level of functional heterogeneity and differentiation (Fig. 4d,e), we found that the increased frequency of CD56^{br} NK cells after IL-275 276 2 treatment, was driven particularly by an increased relative proportion of an activated HLA-II⁺ subset (Fig. 4f). By contrast we found no alterations in the relative composition of CD56^{dim} subsets 277 278 (Fig. 4g and Supplementary Fig. 13). Consistent with activation phenotype and increased expression of CD56 on CD56^{br} NK cells after treatment, we observed a reduced frequency of 279 contaminating CD56^{dim} and CD56^{br} NK cells sorted from the CD56^{br} and CD56^{dim} NK cell gates, 280 respectively at Day 27 (Fig. 4f,g). The alterations in the CD56^{br} NK cells were also transient and 281 282 were not maintained one month after treatment (Supplementary Fig. 13b.c).

Interval low-dose IL-2 immunotherapy induces a systemic and long-lasting anti inflammatory gene expression signature

We next investigated whether, in addition to cellular composition alterations, we could detect IL-285 286 2-induced gene expression changes. On Day 27, we identified 40 genes that are differentially 287 expressed in one or more subsets of unstimulated and stimulated cells (Fig. 5a-c). Consistent with 288 previous flow cytometry analyses¹⁹, CD25 was strongly upregulated on Tregs on Day 27. The 289 differential expressed genes were mostly restricted to the more IL-2-sensitive CD127^{low}CD25^{hi} 290 Treg and CD56^{br} NK cell subsets and could be broadly categorised into CD4⁺ Treg and CD56^{br} 291 NK cell signature genes, reflecting the relative increased proportion of both subsets after iLD-IL-292 2 treatment, as well as the identified reduction in actively dividing CD56^{br} NK cells 293 (Supplementary Fig. 3b). Cycling cells were not present in the stimulated cell populations, 294 potentially due to the preferential sensitivity of cycling cells to apoptosis following activation.

295 Contrary to the differential expression on Day 27, which was observed exclusively in the IL-2sensitive Treg and CD56^{br} subsets, differential expression on Day 55, one month after the last IL-296 297 2 injection, was widespread and displayed a consistent pattern in all five assessed immune subsets 298 (Fig. 6a and Supplementary Fig. 14a,b). These findings indicate that our iLD-IL-2 dosing 299 regimen induces a shared Day 55 gene expression signature in different cell types, which featured 300 most prominently the upregulation of Cytokine Inducible SH2 Containing Protein (CISH), a gene 301 encoding a well-characterised negative regulator of cytokine signalling, and the downregulation 302 of Amphiregulin (AREG), a secreted TNF-inducible protein with pleiotropic roles in 303 inflammation³⁸. We also noted an enrichment of genes associated with cytokine signalling, most 304 notably in the tumour necrosis factor (TNF) signalling pathway, which in addition to CISH and 305 AREG, also included TNFSF14, TNFSF10, STAT1, SGK1, NFKBIZ, NFKBIA, DUSP2, DUSP4, 306 DUSP5, RGS1 and TNFAIP3 (Fig. 6a). Furthermore, we observed a downregulation of several 307 TNF-induced genes that play a central role in curtailing TNF signalling, including the inhibitors of NFkB, NFKBIZ and NFKBIA, RGS1, TNFAIP3 and AREG. Consistent with this observation, 308 309 Oncostatin M (OSM), a pro-inflammatory cytokine shown to be increased in inflammatory bowel disease patients with poor response to anti-TNF therapy³⁹, was also downregulated by iLD-IL-2. 310 Increased expression of TNFSF14, which encodes LIGHT, is notable since decreased expression 311 is associated with higher susceptibility to multiple sclerosis⁴⁰ and in a mouse model of multiple 312

313 sclerosis, LIGHT expression in the brain limits disease severity⁴¹. The widespread detection of this 314 signature in all five T and NK cell populations assessed in this study suggests that this effect is not 315 driven by IL-2 signalling directly but is likely the result of the sustained cellular changes induced

by iLD-IL-2 immunotherapy.

317 Although this Day 55 expression signature was detected in 11 of the 12 participants with Day 55 318 data, we observed heterogeneity among participants for the expression levels of the same genes on 319 Day 27 (Fig. 6b). Some participants exhibited concordant expression changes on Day 27 and Day 5, compared to Day 0, while others showed discordant expression profiles, with CISH being 320 321 downregulated and AREG upregulated on Day 27. Moreover, by principal component analysis 322 (PCA), we found that this concordant-discordant axis, captured by the first principal component (PC1), was able to largely explain the inter-individual heterogeneity of Day 55 signature genes on 323 324 Day 27 and appeared to be associated with IL-2 dose (Supplementary Fig. 14c). Considering this, 325 we derived a linear score to quantify the changes in the Day 55 signature for each participant, 326 referred to as the Day 55 signature score, with higher scores reflecting higher expression of 327 signature genes upregulated on Day 55 (e.g. CISH), and lower expression of signature genes 328 downregulated on Day 55 (e.g. AREG). As expected, the Day 55 signature score showed 329 considerable inter-individual variation (Fig. 6c) that was consistent across different cell types 330 (Supplementary Fig. 14d). This enabled us to correlate changes in signature score, which 331 indicated the direction and amplitude of the modulation of Day 55 genes, with IL-2 dose level. We 332 confirmed that participants receiving higher doses of IL-2 were more likely to have increased 333 signature scores on Day 27 and Day 55 compared the baseline, indicating concordant expression 334 changes, whilst participants receiving lower doses tended to show discordant changes (Fig. 6d,e). 335 The dose-dependence of the Day 55 signature reached statistical significance only when 336 comparing to the participant-specific baseline, but not when inspecting the cross-sectional data at 337 each time point (Supplementary Fig. 14e). This underscores the importance of our longitudinal 338 study design that enhanced our statistical power to identify differential expression patterns.

339

340 Long-lived iLD-IL-2 gene expression alteration is inversely modulated in COVID-19 patients

341 and is progressively induced after the onset of symptoms

342 To extend the support for the existence of the Day 55 gene expression signature, we sought 343 independent evidence of a similar transcriptional response with another immune challenge. 344 Recently, the Oxford COVID-19 Multi-omics Blood Atlas (COMBAT) study⁴² has generated a large single-cell dataset illustrating the changes in blood induced by COVID-19 infection. We 345 346 found a reverse regulation in all immune populations of the 41 identified IL-2 regulated Day 55 347 signature genes, including a marked downregulation of CISH and upregulation of AREG in 348 COVID-19 patients (Fig. 7A). This finding was replicated in an independent cohort of 349 convalescent COVID-19 patients (INCOV)⁴³. In both cohorts, we observed a progressive reduction 350 of the Day 55 gene expression signature, which was particularly pronounced for the first 2-3 weeks 351 after the onset of symptoms (Fig. 7b,c). In the INCOV cohort, follow-up samples taken several 352 months after initial symptoms revealed signs of a slow recovery towards the pre-COVID-19 353 baseline. (Fig. 7c). This progressive induction of the Day 55 signature genes was observed in all 354 COVID-19 disease severity groups and was consistent in all immune populations (Supplementary 355 Fig. 15).

356 In the COMBAT study³⁶, a multiparametric COVID-19-induced gene expression signature, 357 designated as Component 187, featured the differential expression of several Day 55 iLD-IL-2 358 signature genes, including CISH and AREG. Of the 1,419 genes contributing to the COVID-19 359 Component 187, 77 were present in our transcriptional panel. We found that virtually all signature 360 genes upregulated on Day 55 had negative loading scores in the COVID-19 Component 187, and 361 vice versa (Fig. 7d), indicating a strong inverse correlation between the differential gene 362 expression induced by IL-2 treatment and COVID-19. In the COMBAT study, Component 187 363 belonged to Cluster 3, a cluster of similar gene expression signatures associated with all severity 364 groups of COVID-19 patients. We found that Cluster 3 showed the strongest enrichment of the 365 Day 55 Signature genes, compared to all other reported clusters (Fig. 7e). Furthermore, the 366 dynamics of Component 187 over time were similar to that of the Day 55 Signature, though in the 367 opposite direction (Fig. 7f), implying that the set point of a homeostatic cellular network is altered 368 in opposing directions by LD-IL-2 immunotherapy and COVID-19.

369 **Discussion**

Our findings not only extend previous studies^{15–17,28} but also provide new insight into the 370 371 mechanism of action of LD-IL-2 that has practical implications for its clinical use: firstly, we show 372 that LD-IL-2 administered every three days for a period of one month is able to selectively increase 373 the frequency and number of thymic-derived FOXP3⁺HELIOS⁺ Tregs in all 18 study participants 374 analysed, while showing no detectable impact on the expansion or activation of conventional effector T or CD56^{dim} NK cells. We observed a particularly pronounced increase in the frequency 375 376 of naïve FOXP3⁺HELIOS⁺ Tregs after iLD-IL-2 therapy, indicating that the Treg increases are 377 caused by an increased representation of thymic-derived Tregs, and not the proliferation of 378 peripherally-induced Tregs. These findings are consistent with the increased clonal diversity in T 379 cells following an escalating LD-IL-2 regimen in graft-versus-host disease patients^{44,45}. Secondly, 380 we also noted that our iLD-IL-2 schedule did not induce a detectable cytotoxic gene expression 381 signature in any T cell subset, indicating that among T cells iLD-IL-2 has a Treg-specific effect 382 and does not lead to the activation of a pro-inflammatory response. In addition to Tregs, the CD56^{br} 383 NK cell population is also probably contributing to the overall anti-inflammatory effects of iLD-384 IL-2, in an immunoregulatory role, as previously described^{46,47}. Thirdly, iLD-IL-2 was able to reduce IL-21-producing T cells, possibly by antagonizing their differentiation. IL-2 signalling has 385 386 been shown to inhibit the differentiation of T_{FH} cells *in vivo* in mice⁴⁸, and in an *in vitro* model in 387 humans⁴⁹. Consistent with these findings, LD-IL-2 has been shown to decrease the frequency of 388 T_{FH} cells, as defined by cell surface markers⁵⁰, as well as the frequency of marginal zone B cells²⁹ 389 in SLE patients, supporting a role in the regulation of germinal centre reactions. Our results extend 390 these findings to T1D and demonstrate a specific effect of iLD-IL-2 treatment in reducing 391 pathogenic IL-21-producing CXCR5⁺ T_{FH} cells as well as IL-21-producing CXCR5^{low} T cells. 392 Previously, we have shown that a two-fold increase in IL-2, but not IL-21, was responsible for the 393 protective effect conferred by the Idd3 locus (containing IL2 and IL21) in the nonobese diabetic 394 (NOD) mouse model of $T1D^{13}$, and independently that a reduction in IL-21 correlated with 395 increased IL-2⁵¹. In humans, IL-21 has been implicated in the pathogenesis of several autoimmune 396 diseases^{52,53}, particularly $T1D^{21-23}$. Together, these observations lend further support for the use of 397 iLD-IL-2 in T1D as well as in other diseases associated with increased IL-21 production, such as 398 systemic lupus erythematosus, rheumatoid arthritis, and psoriasis. In support of this therapeutic

399 strategy, an anti-IL-21 monoclonal antibody in combination with liraglutide showed promising 400 results in preserving beta-cell function²⁴. Of note, we observed no evidence for the alteration of 401 the frequency of FOXP3⁺ T_{FR} cells, which has been previously shown to play a role in the 402 regulation of T_{FH} cells and the germinal centre reaction^{54,55}.

We also observed a decrease in circulating innate-like CD8⁺ MAIT and $V_{\gamma9}V_{\delta2}$ T cell subsets during treatment and one month after. Since these cells function in anti-viral and anti-bacterial defence⁵⁶, our findings suggest a role of IL-2 immunotherapy in the recruitment of MAIT and $V_{\gamma9}V_{\delta2}$ T cells to tissues following treatment, thereby increasing defence against viral and bacterial infections⁵⁷. This could provide a mechanism for the observed decreased incidence of viral infections in SLE patients undergoing LD-IL-2 immunotherapy⁵⁸.

409 The cellular alterations induced by iLD-IL-2 treatment led to the establishment of a long-lived 410 gene expression signature in all assessed immune populations, which suggest a novel 411 immunoregulatory mechanism of iLD-IL-2. Although the effects of this signature are not yet 412 understood, it is marked by the distinct upregulation of CISH, a well-characterised negative 413 regulator of cytokine signalling whose expression is known to be induced by IL-2, as well as other cvtokines, signalling through the activation of STAT5⁵⁹. In contrast, among the downregulated 414 415 genes, we observed several negative regulators of an inflammatory response at Day 55, including 416 key TNF-induced genes such as TNFAIP3, RGS1 and AREG, suggesting that iLD-IL-2 can 417 decrease the homeostatic levels of TNF for at least one month after the cessation of dosing. Support 418 for the existence of the iLD-IL2-induced long-lived gene expression signature was obtained from analysis of the Oxford COMBAT dataset⁴², where we detected the modulation of the same genes. 419 420 but showing consistent opposite direction of expression following the onset of COVID-19 421 symptoms. We replicated this signature in a large longitudinal cohort of convalescent COVID-19 patients⁴³, which demonstrated a progressive induction of these genes that was particularly 422 423 pronounced in the first two weeks after onset of symptoms. This altered expression profile was 424 consistently sustained for up to 5 months, evidencing the longevity of this immune dysregulation 425 in COVID-19 patients. One possible explanation for the longevity of the signature is that TNF and IL-2 are among the cytokines known to bind to the extracellular matrix $^{33-36}$ and that the retention 426 427 of the cytokines within tissues extends far beyond their initial increases⁶⁰. The establishment of 428 the Day 55 IL-2 signature is dose-dependent at Day 27, likely reflecting a dose-dependent

429 accumulation of injected IL-2 on the extracellular matrix within the interstitial space following 430 subcutaneous dosing. A long-lasting immune alteration that also possibly reflects a continuing 431 inflammatory stimulus or long-lived pro-inflammatory cytokines on the extracellular matrix has 432 been reported in mild COVID-19 patients, with infection inducing a pro-inflammatory response in 433 monocyte-derived macrophages that continues to be detected 3-5 months following SARS-CoV-2 434 infection⁶¹. In a separate study, pro-inflammatory markers such as IL-8 and sTIM-3 were still 435 elevated four months after the cessation of COVID-19 symptoms in patients having had mild or 436 moderate disease, but the increases resolved eight months post-infection except in patients with 437 long COVID⁶².

438 We hypothesise that the balance between pro- and anti-inflammatory cytokines bound to the 439 extracellular matrix provides a regulatory mechanism to control immune responses. Circulating 440 immune cells can constantly integrate this information through a combination of cell-type specific 441 receptors. Under homeostatic conditions this provides a dynamic buffer system preventing 442 excessive (or potentially chronic) immune activation. A perturbation of this balance via either 443 sustained regulatory (e.g. iLD-IL-2 immunotherapy) or inflammatory (e.g. SARS-CoV-2 444 infection) environment can alter the composition of the soluble mediators contained in the 445 extracellular matrix, and consequently affect the interaction between the immune system and the 446 local environment, leading to the remodelling of their transcriptional profile and an alteration of 447 their threshold for further stimulation. Such a complex system is likely critical not only to prolong 448 the biological activity of key immune mediators such as TNF and IL-2, but also to control site 449 specificity to prevent improper signalling in the wrong physiological context. These findings are 450 also consistent with our observation that pro-inflammatory gene expression is progressively 451 induced after infection, and that it could contribute to the long-lasting systemic alterations 452 associated with the persistence of clinical manifestations in long COVID patients.

453 A limitation of this study is that we were not able to elucidate the exact mechanism underpinning 454 the induction of the identified long-lived gene expression signature and how this is regulated by 455 iLD-IL-2 or COVID-19. Although we show that iLD-IL-2 can induce this signature, it is certainly 456 not the only responsible factor, as a reversed expression can also be induced in a completely 457 different pathophysiological context such as COVID-19. Furthermore, markers of disease activity 458 and progression are limited in T1D and were not collected for the DILfrequency patients, which

459 precludes the analysis of how they are associated with these gene expression alterations. A more 460 comprehensive investigation of these questions will need to be performed in an appropriate follow 461 up cohort such as the recently completed Interleukin-2 Therapy of Autoimmunity in Diabetes 462 (ITAD) trial⁶³. The findings from this study will inform the design of suitable follow up 463 experiments in this and other studies of iLD-IL-2 in multiple diseases and will be critical to better 464 understand both the longevity of the signature and how it is associated with clinical outcomes. 465 Another limitation is that the interpretation of the results may be dependent on our specific iLD-466 IL-2 dosing regimen. Although it is likely that most regimens will induce very similar results, it 467 will be important to validate these findings in different dosing schedules. Given the diverse range 468 of conditions where LD-IL-2 immunotherapy is being trialled, it is critical to better understand 469 how dosing regimen affects the drug's mechanism of action, and to tailor it to the disease-specific 470 applications, including when best to administer IL-2 during the course of standard care or as a way 471 of maintaining the clinical benefits of ongoing treatments⁶⁴, for example, in the use of anti-CD3 472 (teplizumab) to treat and prevent $T1D^{65}$.

473 Taken together, our findings provide a better understanding of the mechanism of action of LD-IL-474 2 immunotherapy. In the past there have been concerns over the very short half-life of recombinant 475 IL-2 in vivo and that NK cell expansion might be detrimental, which have led to the development 476 of genetically-modified IL-2 muteins with increased half-life and preferential binding to the highaffinity trimeric IL-2 receptor in order to reduce CD56^{br} NK cell stimulation. Our results 477 478 demonstrating a long-lived gene expression signature associated with potential anti-inflammatory 479 effects, detectable one month after the end of aldesleukin treatment, alleviate some of these 480 concerns and support the therapeutic potential of IL-2 that is not engineered for longer in vivo half-481 life or preferential binding to the high affinity IL-2 receptor, given intermittently and at low doses. 482 Our study adds to the good track record of using low-dose recombinant IL-2 and confirms its very 483 strong safety profile, which is critical for the potential long-term use of LD-IL-2 immunotherapy 484 for diseases such as T1D in which the target patient population will consist mainly of children, including the possible future use of iLD-IL-2 treatment in the prevention of T1D diagnosis, as 485 486 demonstrated in recent teplizumab trials⁶⁵ and for T1D treatment with other monoclonal antibodies such as golimumab (anti-TNF)^{66,67}. Additionally, iLD-IL-2 treatment could be trialled in 487 488 recovering COVID-19 patients, after acute inflammation has been resolved, to determine if such

treatment hastens the restoration of normal immune homeostasis and perhaps reduce theoccurrence of long COVID complications.

Methods 491

492 The study was performed in accordance with the guidelines for good clinical practice and the 493 Declaration of Helsinki. Study participants included T1D patients enrolled in two single centre 494 mechanistic studies of low-dose recombinant IL-2 (aldesleukin) immunotherapy: (i) the Adaptive 495 study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D), a non-randomised single 496 IL-2 dosing study20; and (ii) the Adaptive study of IL-2 dose frequency on regulatory T cells in 497 type 1 diabetes (DIL frequency), a response-adaptive trial of repeated doses of IL-2 administered 498 using an interval dosing approach21. Approval was obtained from the Health Research 499 Authority, National Research Ethics Service (13/EE/0020 and 14/EE/1057, for the DILT1D and 500 DIL frequency studies, respectively), London, United Kingdom. The trials were registered at the 501 International Standard Randomised Controlled Trial Number Register (ISRCTN27852285 and 502 ISRCTN40319192) and ClinicalTrials.gov (NCT01827735 and NCT02265809). The study 503 protocols were published in advance of the completion and final analysis of the trials^{68,69}. All 504

participants provided written informed consent prior to their participation in the studies.

505 Study design and participants

506 Study participants comprised 18 T1D patients enrolled in the DIL frequency study¹⁹. All 18 study 507 participants, who were all adult patients diagnosed with T1D over 60 months before recruitment 508 into the study, were selected from the 3-day interval group and were treated with IL-2 with doses 509 ranging from 0.2 to $0.47 \times 10^6 \text{ IU/m}^2$.

510 FACS-based replication of the single-cell multiomics findings was performed in two follow-up cohorts: (i) a single-dosing cohort, comprising 6 DILT1D patients¹⁸ treated with a single dose of 511 IL-2 ranging from 0.6 to 1.5 x 10^6 IU/m²; and (ii) a multiple dosing cohort, comprising 5 512 513 DIL frequency patients from the three-day dosing regimen, treated with IL-2 doses ranging from 514 0.2 to 0.32×10^6 IU/m². Study participants' characteristics and immune profiling at baseline are 515 summarised in Supplementary Table 1.

516

517 Flow cytometry

518 Flow cytometric characterisation of fresh whole-blood samples from the DIL frequency study 519 participants was performed at each visit within 4 h of phlebotomy, as previously described²⁰. 520 Briefly, 150 µl whole blood were incubated for 45 min at room temperature with fluorochromeconjugated antibodies (Supplementary Table 2, 2nd panel). Red blood cells were then lysed (BD 521 522 FACS Lysing solution). The absolute number of the main lymphocyte populations, including 523 CD4⁺ T, CD8⁺ T and CD56⁺ NK cells, was assessed using a whole-blood BD Multitest 6-Color 524 TBNK assay using BD Trucount Tubes according to the manufacturers' instructions (BD Biosciences) at each visit. Absolute numbers of CD4⁺ Tregs and Tconvs, and CD56^{br} and CD56^{dim} 525 526 NK cells were derived by multiplying the absolute number of CD4⁺T cells and CD56⁺ NK cells 527 by the appropriate percentages derived from the panel described above.

528 For the intracellular immunostainings, cryopreserved PBMCs were thawed at 37°C and 529 resuspended drop-by-drop in X-VIVO 15 (Lonza) with 1% heat-inactivated, filtered human AB 530 serum (Sigma). PBMC samples were selected from 10 visits (Days 0, 1, 2, 3, 4, 5, 6, 9, 14 and 28) 531 from each patient from the single-dosing and 4 visits (Days 0, 3, 27 and 55) for the multiple dosing 532 cohort. PBMCs were then washed in PBS, incubated with Fixable Viability Dye eFluor 780 533 (eBioscience) for 15 min at 4°C and stained with fluorochrome-conjugated antibodies against 534 surface-expressed markers (Supplementary Table 2) for 45 min at 4°C. Fixation and 535 permeabilisation was performed using the FOXP3 Fix/Perm Buffer Set (eBioscience) according 536 to the manufacturer's instructions, and cells were then stained with fluorochrome-conjugated 537 antibodies against intracellular markers (Supplementary Table 2) for 1 h at room temperature.

Immunostained samples were acquired on a BD Fortessa (BD Biosciences) flow cytometer with
FACSDiva software (BD Biosciences) and analysed using FlowJo (Tree Star, Inc.). Information
for all fluorochrome-conjugated antibody panels used in this study is provided in Supplementary
Table 2.

542 In vitro Treg suppression assay

A total of 12 DIL frequency participants were selected for this analysis, including nine participants that were also included in the single-cell analyses. For each participant, cells sampled from three time points were used: Day 0, Day 24 and Day 55. Cryopreserved PBMCs were thawed as

546 described above and stained with a cocktail of monoclonal antibodies (Supplementary Table 2) 547 for cell sorting. Suppression assays were established in V-bottom 96-well plates by sorting 500 548 CD4⁺CD25^{-/lo}CD127⁺ effector T cells (Teffs) in the presence or absence of 549 CD4⁺CD25^{high}CD127^{low} Tregs at various ratios (Treg:Teff 0:1, 1:4, 1:2 and 1:1) with 1×10^3 550 CD19⁺ B cells, using the BD FACSAria III flow cytometer automated cell deposition unit (BD 551 Biosciences). Cells were sorted into in 150 µl X-VIVO 15 supplemented with Penicillin-552 Streptomycin-Fungizone (Gibco) and 10% heat-inactivated, filtered human AB sera, stimulated 553 with PHA (4 µg/ml; Alere) and incubated at 37°C, 5% CO₂, for 5 days. Proliferation was assessed 554 by the addition of 0.5 µCi/well [3H] thymidine (PerkinElmer) for the final 20 h of co-culture. 555 Conditions were run in 5 replicates, and proliferation readings (counts per minute [CPM]) 556 averaged. Two samples with averaged proliferation less than 1,000 CPM from the Teff wells alone 557 were excluded from the analysis. The percentage suppression in each culture was calculated using 558 the following formula: percent suppression = $100 - [(CPM \text{ in the presence of Tregs} \div CPM \text{ in the}$ 559 absence of Tregs) \times 100]. All time points from a participant were analysed concurrently.

560

561 Single-cell multiomics: cell preparation and capture

562 Single-cell multiomics profiling was performed using the BD Rhapsody system on PBMC aliquots from 13 of the DIL frequency participants treated with the 3-day interval dosing schedule 563 564 (Supplementary Table 1) collected at the baseline visit (Day 0), 3 days after the last dose of IL-565 2, immediately prior to the last IL-2 infusion of the dosing phase (Day 27) and one month after the 566 last dose of IL-2 (Day 55). Cryopreserved PBMCs were thawed at 37°C and resuspended drop-567 by-drop in X-VIVO 15 with 1% heat-inactivated, filtered human AB serum. After washing in PBS, 568 cells were incubated with Fixable Viability Dye eFluor 780 (eBioscience) for 10 min at room 569 temperature, washed with cold PBS + 2% FBS and incubated for 30 min at 4°C with fluorochrome-570 conjugated antibodies for sorting (Supplementary Table 2). Cells were then washed two times 571 and resuspended in cold PBS + 1% FBS for cell sorting at 4°C in a BD FACSAria Fusion sorter 572 (BD Biosciences). The following T and NK cell subsets were sorted from each participant at each visit: (i) CD3⁻CD56^{hi} (CD56^{br}NK; (ii) CD3⁻CD56⁺ (CD56^{dim}NK; (iii) CD3⁺CD8⁺ (CD8⁺ T); (iv) 573 CD3⁺CD4⁺ CD25^{-/low} (CD4⁺ Tconv); and (v) CD3⁺CD4⁺ CD127^{low}CD25^{hi} (CD4⁺ Treg). We 574

aimed to sort a total of 130,000 cells for the Day 0 and Day 55 visits and 160,000 for the Day 27
visit, with the following proportion of each of the sorted cell populations: 30% CD4⁺ Treg; 25%
CD4⁺ Tconv and CD8⁺ T; 12% CD56^{br} NK and 8% CD56^{dim} NK cells.

578 Following cell sorting, each sorted subset was labelled with the respective sample barcoding 579 antibody (sample multiplexing kit; BD Biosciences) for 20 min at 4°C to allow for the 580 identification of the sorting gate and visit of each captured single cell. To minimise day-to-day 581 variation, we processed the three PBMC samples corresponding to the three visits from each 582 participant on the same day. As the number of barcoded oligo-conjugated antibodies available in 583 the kit was less than the total number of sorted subsets, we combined the CD4⁺ Treg and CD56^{dim} 584 NK cells as well as the CD4⁺ Tconv and CD56^{br} NK cells from each visit and labelled the pooled 585 cells with the same barcode. These combined subsets were chosen for their highly differentiated 586 transcriptional and proteomics profile, which allowed robust separation of the respective original 587 subsets at the analysis stage. Cells were then washed three times with BD Sample Buffer (BD 588 Biosciences) at 4°C to remove any residual unbound barcoding antibody and then pooled together 589 for downstream processing.

590 To profile unstimulated cells, half of the pooled cells volume (corresponding to ~ 210.000 cells) 591 were initially incubated at 4°C for 5 min with human Fc block (BD Biosciences) and then for a 592 further 45 min with a master mix of 65 oligo-conjugated AbSeq antibodies (BD Bioscience; 593 **Supplementary Table 2**). Cells were then washed three times with BD Sample Buffer at 4°C to 594 remove residual unbound oligo-conjugated AbSeq antibodies, resuspended in 500 ul cold BD 595 Sample buffer and filtered through a sterile 50 µm Filcon cup-type filter (BD Biosciences) for cell 596 counting. Samples were then resuspended in 620 µl of cold BD sample buffer at a concentration 597 of 40 cells/ μ l - for an estimated capture rate of ~20,000 single-cells / cartridge - and immediately 598 loaded on two BD Rhapsody cartridges (BD Biosciences) for single-cell capture.

For *in vitro* stimulation, the remaining volume from the pooled cells was washed at 4°C and resuspended in X-VIVO 15 + 10% heat-inactivated, filtered human AB serum at a final concentration of 2×10^6 cells/ml. A volume of 100 µl (~200,000 cells) was then incubated in one well of a round-bottom 96-well plate at 37°C for 90 minutes with a PMA and ionomycin cell stimulation cocktail (eBioscience), in the absence of protein transport inhibitors. Cells were

harvested into a FACS tube, washed with PBS + 2% FBS and processed for cell capture, as detailed
above for the unstimulated cells.

606

607 Single-cell multiomics: cDNA library preparation and sequencing

Single-cell capture, and cDNA library preparation was performed using the BD Rhapsody Express single-cell analysis system (BD Biosciences), according to the manufacturer's instructions. cDNA was initially amplified for 11 cycles (PCR1) using the pre-designed Human T-cell Expression primer panel (BD Biosciences) containing 259 primer pairs, together with a custom designed primer panel containing 306 primer pairs (BD Biosciences), described previously²⁰. A total of 565 primer pairs targeting 534 different genes were targeted for amplification with this targeted panel (Supplementary Table 2).

615 The resulting PCR1 products were purified using AMPure XP magnetic beads (Beckman Coulter) 616 and the respective mRNA and AbSeq/sample tag products were separated based on size selection, 617 using different bead ratios ($0.7 \times$ and $1.2 \times$, respectively). The purified mRNA and sample tag PCR1 618 products were further amplified (10 cycles) using a nested PCR approach and the resulting PCR2 619 products purified by size selection $(0.8 \times \text{ and } 1.2 \times \text{ for the mRNA} \text{ and sample tag libraries},$ 620 respectively). The concentration, size and integrity of the resulting PCR products was assessed 621 using both Qubit (High Sensitivity dsDNA kit; Thermo Fisher) and the Agilent 4200 Tapestation 622 system (Agilent). The final products were normalised to 2.5 ng/ μ l (mRNA), 1.1 ng/ μ l (sample tag) 623 and 0.35 ng/µl (AbSeq) and underwent a final round of amplification (six cycles for mRNA and 624 sample tag and 7 cycles for AbSeq) using indexes for Illumina sequencing to prepare the final 625 libraries. Final libraries were quantified using Qubit and Agilent Tapestation and pooled 626 (~29/67/4% mRNA/AbSeq/sample tag ratio) to achieve a final concentration of 5 nM. Final pooled 627 libraries were spiked with 15% PhiX control DNA to increase sequence complexity and sequenced 628 (150 bp paired-end) on a NovaSeq 6000 sequencer (Illumina).

629

630 **Pre-processing of single-cell sequencing data**

631 The single-cell sequencing reads were processed following instructions from BD Biosciences 632 described earlier²⁷, with slight modifications. First, low-quality read pairs were removed based on 633 read length, mean base quality score and highest single-nucleotide frequency. High-quality R1 634 reads were analysed to extract cell labels and unique molecular identifier (UMI) sequences. High-635 quality R2 reads were aligned to the reference panel sequences using Bowtie2⁷⁰. Reads having the identical cell labels and UMI sequences and aligned to the same gene were collapsed into a single 636 637 molecule. To correct sequencing and PCR errors, the obtained counts were adjusted by a recursive 638 substitution error correction (RSEC) algorithm developed by BD Biosciences. The sampling time 639 point and sorting gate of origin of each cell were labelled using information from barcoded oligo-640 conjugated antibodies. Cells without barcoding information were labelled as "tag N/A", and cells 641 with two or more barcodes were labelled as "multiplet". We note that sample barcoding and AbSeq 642 staining efficiency was compromised in CD56^{br} NK cells. As the quality of the main mRNA library was not affected by this technical issue, CD56^{br} NK cells without barcoding information were 643 644 included in the quality control and clustering step, but excluded from subsequent analyses 645 dependent on sampling time point (see below). This led to a significant reduction in the number of 646 CD56^{br} NK cells analysed and a concomitant reduction in statistical power to identify IL-2-induced 647 alterations. Nevertheless, we also note that our cell-enrichment strategy compensated for this cell 648 loss due to technical reasons and provided sufficient resolution to dissect the heterogeneity of the 649 rare population of CD56⁺ NK cells.

650

651 **Doublet scoring**

Doublet scoring was performed on each sample separately using Scrublet⁷¹. Briefly, this method simulates synthetic doublets by sampling pairs of cells and then scores each cell by its similarity to the simulated doublets. For each sample, count matrices for RNA and AbSeq data were concatenated and used as the input. The method was modified to exclude known multiplet-tagged cells from the doublet simulation while retaining them for scoring. The doublet score was used to help identify clusters of doublets in subsequent quality control stages.

659 Normalisation, integration, dimensionality reduction and clustering

660 Data normalisation was performed using Seurat⁷². The RNA count matrices were normalised by 661 log normalisation. Specifically, the RNA counts for each cell were (i) divided by the total counts 662 for that cell, (ii) multiplied by a scale factor of 10,000, and (iii) natural-log transformed after 663 adding one pseudo count. The AbSeq counts for each cell were considered compositional and 664 normalised by a centred log ratio transformation⁷³. Normalised RNA and AbSeq expression 665 matrices were then centred and scaled. Specifically, each feature was linearly regressed against 666 selected latent variables including the number of RNA and AbSeq features, and the donor of origin, 667 where appliable. The resulting residuals were mean-centred and divided by their standard 668 deviations.

669 Integration of the scaled AbSeq expression matrices from different participants were performed 670 using a combination of canonical correlation analysis (CCA) and identification of mutual nearest 671 neighbours (MNNs), implemented in Seurat⁷². After integration was performed, the updated 672 AbSeq expression matrices produced by the integration algorithm were used in subsequent 673 dimensionality reduction and clustering.

674 Dimensionality reduction and clustering were performed using Seurat⁷². Specifically, principal 675 components (PCs) were calculated separately for each assay using the top variable features of the 676 scaled or integrated expression matrices, and a weighted nearest neighbour (WNN) graph as well 677 as a weighted shared nearest neighbour (WSNN) graph were generated on the ten top PCs from each assay, unless otherwise specified. We used k = 30 nearest neighbours for each cell. Uniform 678 Manifold Approximation and Projection (UMAP)⁷⁴ embeddings were then calculated based on the 679 680 WNN graph. The Louvain algorithm⁷⁵ was applied to identify clusters of cells based on a WSNN 681 graph, at the selected resolution level. Clusters with fewer than ten cells were removed. The 682 resulting clusters were manually annotated based on marker genes and sorting gate information to 683 elucidate cell types and label suspicious clusters.

684

685 Data quality control

686 The BD Rhapsody single-cell sequencing data generated in this study was processed through a 687 pipeline consisting of multiple quality control steps as described below. Methodological details of 688 each step are specified in previous sections. The single-cell sequencing data of each sample (i.e. 689 the collection of stimulated and unstimulated cells for a single participant) were pre-processed to 690 obtain two annotated count matrices (RNA and AbSeq). We performed data normalisation, 691 dimensionality reduction and clustering for each sample. Specifically, 30 RNA principal 692 components (PCs) and 30 AbSeq PCs were used to generate the WNN and WSNN graphs, and 693 clustering was performed at resolution 0.5.

Within each sample, cells meeting one of the following criteria were removed: (1) cells that are labelled as "multiplet" or in clusters with high doublet scores; (2) cells labelled as "tag N/A", except those in clusters annotated as $CD56^{br}$; (3) cells in clusters with very low RNA counts and very low or very high AbSeq counts; (4) cells in clusters annotated as monocyte or B cell contamination; (5) cells labelled as DN T cells.

The filtered cells from each participant were merged according to the stimulation status into two datasets (unstimulated cells and *in vitro* stimulated cells). Both stimulated and unstimulated cells were then processed in the same way unless otherwise specified. We performed data normalisation, dimensionality reduction and clustering for each merged dataset. Specifically, clustering was performed at resolution 0.7 (unstimulated cells) or 1.5 (stimulated cells). Doublet clusters were manually annotated and removed. Data normalisation, dimensionality reduction and clustering were performed again. Specifically, clustering was performed at resolution 0.5.

706 Cells in each filtered dataset were subsequently partitioned into four major groups (CD4⁺ Treg, 707 CD4⁺ Tconv, CD8⁺ T and CD56⁺ NK cells) based on cluster annotations and sorting gates of 708 origin. In addition, unstimulated cells in clusters marked by genes related to cell cycle were 709 grouped as cycling cells. We chose to partition cycling cells into one separate group based on the 710 following considerations: (i) cycling cells were relatively rare in numbers (0.72% of total 711 unstimulated cells); (ii) cycling cells clusters had well-defined mRNA markers; (iii) The 712 phenotypical differences between cycling cells and their non-cycling counterparts were potentially 713 larger than the heterogeneity within each major cell populations.

After partitioning, doublet clusters were manually annotated and removed. Data normalisation, dimensionality reduction, integration and clustering were performed in each group of partitioned cells. Specifically, clustering was performed at resolution 0.5. Finally, data normalisation, dimensionality reduction, and clustering were performed again.

718 Owing to the aforementioned technical limitations with AbSeq staining in CD56^{br} NK cells, AbSeq 719 data was not used in dimensionality reduction and clustering of NK cells. The following 720 resolutions were used for the final clustering: unstimulated Tregs, 0.6; unstimulated Tconvs, 0.5; 721 unstimulated CD8, 0.5; unstimulated NK, 0.3; unstimulated cycling cells, 0.5; stimulated Tregs, 722 0.5; stimulated Tconvs, 0.4; stimulated CD8: 0.5; stimulated NK: 0.5. The resulting partitioned 723 datasets were used for subsequent analyses. We note that one PBMC aliquot (corresponding to the 724 Day 55 visit of Participant 8) vielded very low cell numbers (N = 603 unstimulated and N = 67725 stimulated cells) and displayed a compromised FACS staining profile. These cells were included 726 in quality control and clustering procedures but excluded from downstream analyses. All other 38 727 samples corresponding to 38 visits yielded the expected cell frequencies and numbers.

728

729 Single-cell proliferation scores

730 Single-cell proliferation scores were calculated using a previously described approach⁷⁶, which is 731 based on the average normalised expression levels of a pre-selected set of 11 mRNA features related to cell cycle (AURKB, HMGB2, HMMR, MCM4, MKI67, PCLAF, PCNA, TK1, TOP2A, 732 733 TYMS, and UBE2C), subtracted by the aggregated expression of a control set of 50 randomly 734 selected mRNA features. The proliferation scores were used to identify two cycling clusters from 735 the 15 functional T and NK cell subsets identified in blood from the initial clustering 736 (Supplementary Fig. 3a). We noted that the distinct co-expression of these cell-cycle genes 737 present in our targeted transcriptional panel superseded more subtle functional differences and 738 aggregated all cycling T and NK cells into two respective clusters, regardless of their original 739 sorting gate. Given this lack of functional differentiation and to avoid the potential overwhelming 740 effect of these cell-cycle genes on the resulting clustering visualisation, we opted to separate these 741 cycling T and NK cells from the rest of the cells included in subsequent clustering steps to assess 742 IL-2-induced changes in their relative frequency in blood.

743

744 Cluster annotation

745 Functional annotation of the resulting clusters was performed manually based on the cluster-746 specific differential expression of the mRNA and protein markers (summarised in **Supplementary** 747 Data 1). Sample tagging information, corresponding to sorting gate information, was used to sub-748 cluster the five main immune populations (CD4⁺ CD127^{low}CD25^{hi} Treg; CD4⁺ CD25^{-/low} Tconv; CD8⁺ T; CD56^{br} NK and CD56^{dim} NK cells). The use of a bespoke targeted single-cell approach 749 combined with a cell-subset enrichment strategy provided a high-resolution map of the 750 751 heterogeneity of these cell populations – and particularly of the rare circulating CD4⁺ Treg and 752 CD56^{br} NK cell subsets.

We note that a consequence of the cell-subset enrichment strategy used in this study is that the frequency of the T and NK cell subsets described in this dataset do not directly represent their frequency in whole blood. The aim of this study was not to identify changes in the global composition of PBMCs, but to specifically focus on the T and NK cell subsets. The pre-purification of the Treg and CD56^{br} NK subsets was central to the resolution of this approach and provided greater power to dissect their functional heterogeneity and investigate how their relative composition was modified by LD-IL-2 immunotherapy

760

761 Functional annotation of CD4⁺ CD127^{low}CD25^{hi} T cell clusters

Owing to our cell-subset enrichment strategy, we obtained a high-resolution map depicting the heterogeneity of CD127^{low}CD25^{hi} T cells in blood, with 13 distinct clusters identified in unstimulated cells (**Supplementary Fig. 4a**) and 12 in *in vitro* stimulated cells (**Supplementary Fig. 4b**). Overall, we found consistency in the functional annotation of the identified subsets in stimulated and unstimulated cells, with a clear demarcation of the naïve and memory subsets.

Expression of the canonical Treg transcription factors *FOXP3* and *IKZF2* (encoding HELIOS) was
 used to identify three distinct groups of clusters, corresponding to different populations of
 CD127^{low}CD25^{hi} T cells: (i) CD45RA⁺ FOXP3⁺HELIOS⁺ clusters (depicted in green)

corresponding to thymic-derived naïve Tregs; (ii) CD45RA⁻ FOXP3⁺HELIOS⁺ clusters (depicted
in blue) corresponding to memory Tregs with suppressive function; and (iii) CD45RA⁻ CD25⁺
FOXP3⁻HELIOS⁻ clusters (depicted in red) corresponding to a small subset of Teffs expressing
CD25 likely due to recent activation (Supplementary Fig. 5). Additional clusters showing
variable expression of FOXP3 but lack of HELIOS expression (FOXP3⁺HELIOS⁻ clusters) were
depicted in black, and represent a more heterogeneous group of Treg subsets, containing a mix of
thymic-derived and induced Treg subsets.

As expected, most of the cells within the CD127^{low}CD25^{hi} Treg gate showed concomitant 777 778 expression of FOXP3 and HELIOS, which is consistent with their largely demethylated FOXP3 779 Treg-specific demethylated region (TSDR)³⁷, the hallmark of *bona fide* thymic Tregs. 780 Furthermore, we were able to identify a trajectory of thymic Treg differentiation, originating from 781 the naïve FOXP3⁺HELIOS⁺ Tregs (cluster 0). Memory FOXP3⁺HELIOS⁺ Tregs displayed more 782 heterogeneity and included four distinct subsets in unstimulated cells, including a cluster of CD80⁺ 783 Tregs characterised by elevated expression of tissue-homing receptors (cluster 7) and a cluster of 784 effector Tregs (cluster 1) typically marked by the expression of HLA class II and other effector 785 Treg markers such as CD39 and GITR (Supplementary Fig. 4a). We have also identified a subset 786 of CD45RA⁺ naïve cells (cluster 2) showing much lower expression of FOXP3 and HELIOS 787 compared to the classical naïve Treg cluster. This likely corresponds to a subset of homeostatically-expanded CD45RA⁺ T cells upregulating CD25 that we have previously 788 789 characterised⁷⁷. Consistent with this non-Treg profile, these CD25⁺ naïve T cells upregulated the 790 expression of IL-2 upon *in vitro* stimulation (Supplementary Fig. 5f). The expression of IL-2 in 791 stimulated cells was also a hallmark of the CD25⁺ FOXP3⁻HELIOS⁻ Teff clusters and allowed us 792 to further refine their functional heterogeneity. Moreover, the relative frequency of CD45RA⁻ 793 FOXP3⁻HELIOS⁻ cells identified in this single-cell dataset is consistent with the frequency of cells identified by FACS as cytokine-producing FOXP3-HELIOS- cells in the CD127^{low}CD25^{hi} Treg 794 795 gate that we have previously shown to contain a methylated TSDR³⁷, further indicating that they 796 correspond to a small proportion of activated CD25⁺ FOXP3⁻HELIOS⁻ Teffs captured in the 797 CD127^{low}CD25^{hi} Treg gate.

798

799 Functional annotation of CD56⁺ NK cell clusters

800 In contrast to T cells, we found much lower heterogeneity in NK cells (Fig. 4d and Supplementary 801 Fig. 13). In addition, the technical issue affecting the efficiency of the AbSeq staining on CD56^{br} 802 NK cells, precluded the use of protein data for the clustering and annotation of the CD56⁺ NK 803 cells, which also contributed to a lower resolution of the clusters. Nevertheless, our cell-804 enrichment strategy allowed us to generate a comprehensive single-cell map of NK cell heterogeneity, most notably of the rare, IL-2-sensitive CD56^{br} NK population. We observed 805 differentiation of CD56^{br} NK cells from a rare progenitor subset marked by the expression of genes 806 807 associated with haematopoiesis such as SOX4 and KIT, and characterization of two functional 808 subsets associated with a trajectory of CD56^{br} NK cell maturation, which was marked by HLA 809 class II gene expression in the more differentiated cells. In contrast, CD56^{dim} NK cells showed a 810 distinct transcriptional profile of two distinct subsets, reflecting a gradient of NK cell activation associated with the acquisition of a cytotoxic profile (Fig. 4d and Supplementary Fig. 13). These 811 findings support a distinct functional differentiation between the CD56^{dim} and CD56^{br} subsets, 812 which allowed clear identification a fraction of CD56^{dim} NK cells sorted in the CD56^{br} gate, as 813 well as a fraction of CD56^{br} NK cells sorted within the CD56^{dim} gate (Fig. 4e). 814

815

816 Differential abundance analysis

817 To identify specific cell frequency changes across different sampling time points, we calculated 818 the frequency of each cell type annotated. A cell type was defined as a group of cells from the 819 same cluster or several similar clusters, after removing cells not sorted from the corresponding 820 gate. The frequency of each cell type for each participant and each time point was calculated as 821 the proportion of that cell type within all cells from the same participant, time point and sorting 822 gate of origin. For each cell type, a two-sided Wilcoxon signed-rank test was performed to compare 823 the frequencies at Day 0 with the frequencies at Day 27 or Day 55 in the 13 participants selected 824 for single-cell analysis. Benjamini-Hochberg FDR correction was applied after pooling all 825 resulting P values. For each cell type and each participant, the \log_2 fold change values between 826 corresponding frequency values were calculated and visualised. We note that cells were compared

only if they were from the same sorting gate, as cells from different sorting gates were pooled indesignated proportions that are not biologically relevant.

829

830 Generation and normalisation of pseudo-bulk expression data

831 For the DILfreq dataset, unstimulated and stimulated cells were separately partitioned into five groups (Treg, Tconv, CD8, CD56^{br} and CD56^{dim}), after removing cells not sorted from the 832 833 corresponding gate. In each group, cells from the same participant, time point and stimulation 834 status were aggregated into one pseudo-bulk sample by summarising raw counts of each mRNA 835 or AbSeq feature. For the COMBAT and INCOV datasets, the pseudo-bulk expression data for 836 each participant and each cell type were obtained from the authors, and samples with less than 837 2,000 total RNA counts were removed. For the INCOV dataset, samples from non-COVID-19, 838 immunocompromised or immunosuppressed participants were additionally removed.

839

840 Differential expression analysis

841 Differential expression analysis was performed separately for RNA and AbSeq data from raw 842 pseudo-bulk counts using DESeq2⁷⁸. Specifically, the likelihood ratio test was used, with a full 843 model including time points and the participants as independent variables, and a reduced model 844 including only participants as the independent variable. The apeglm method⁷⁹ was applied to 845 shrink the resulting fold change values, and the Benjamini-Hochberg FDR correction was applied 846 after pooling all resulting P values (Supplementary Data 2). Genes with either (i) absolute log2 847 fold change values equal to or greater than 0.4 and FDR-adjusted P values less than 0.01, or (ii) 848 FDR-adjusted P values less than 1×10^{-10} , were selected as significantly differentially expressed 849 genes, unless otherwise noted. Participant-specific log₂ fold change values were calculated directly 850 from the normalised pseudo-bulk expression data.

851

852 Day 55 signature scores

Forty-one genes that were significantly upregulated or downregulated in at least one unstimulated cell population comparing Day 55 with Day 0 were defined as Day 55 signature genes, from which the Day 55 signature scores were calculated. Within each dataset, the Day 55 signature score was defined for each pseudo-bulk sample as the sum of z-scores of normalised expression levels of upregulated signature genes, subtracted by that of downregulated signature genes. For each participant and cell type in the DILfrequency dataset, the Δ signature scores were defined as the signature score differences between Day 27 or Day 55 and Day 0, as indicated.

860

861 **Pseudo-time trajectory analysis**

Pseudo-time trajectory analysis was performed using Slingshot⁸⁰ and tradeSeq⁸¹. First, 10dimensional UMAP embeddings were generated for stimulated CD4⁺ T cells based on RNA and AbSeq data, as described above. Second, the Slingshot algorithm was applied to UMAP data and the manually annotated cluster labels, with naïve cells selected as the starting point, and other parameters set to default. Finally, the resulting pseudo-time data were used as the input for the tradeSeq algorithm to model the expression levels of each gene along each trajectory.

868

869 **Data availability**

The single-cell sequencing data generated in this study have been deposited in Gene Expression
Omnibus (GEO) under accession code GSE201197
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE201197).

874 Code availability

- The custom code used in the study for data analyses and visualisation has been deposited in
- 876 Zenodo (<u>https://doi.org/10.5281/zenodo.7116340</u>).

877 Acknowledgements

878 We thank all participants in DILT1D and DILfrequency for their generous contribution to this 879 study. The authors also acknowledge the support of the NIHR Cambridge Biomedical Research 880 Centre and the Cambridge Clinical Trial Unit for trial coordination; the NIHR/Wellcome Trust 881 Clinical Research Facility and Addenbrooke's Centre for Clinical Investigation for clinical 882 facilities; the Department of Clinical Immunology, Addenbrooke's Hospital; the JDRF/Wellcome 883 Diabetes and Inflammation laboratory sample processing team (led by Helen Stevens) and 884 information technology and administration team (led by Judy Brown) and data teams at the 885 Cambridge Institute for Medical Research. We thank Shannah Donhou, Sarune Kacinskaite and 886 Heather McMurray, University of Oxford for sample collection and preparation, and members of 887 the Diabetes and Inflammation Laboratory for critical discussion. We thank Justin Whalley, 888 Georgina Kerr, Brian Marsden and Julian Knight, University of Oxford, for providing access to 889 clinical data collected from the COMBAT cohort. We also thank Yapeng Su, and Dan Yuan from 890 Institute for Systems Biology, and Jason D. Goldman from Swedish Medical Center, for providing 891 access to the annotated single-cell data collected from the INCOV cohort.

892 Funding

893 This work was supported by the Sir Jules Thorn Trust (13/JTA (OCT2013/DR/1044)), the JDRF 894 (1-SRA-2019-657-A-N), and the NIHR Cambridge Biomedical Research Centre. The Diabetes 895 and Inflammation Laboratory was supported by a strategic award from the Wellcome 896 (107212/A/15/Z) and the JDRF (4-SRA-2017-473-A-A). JYZ was supported by the China 897 Scholarship Council-University of Oxford Scholarship. The research was supported by the 898 Wellcome Trust Core Award Grant Number 203141/Z/16/Z with additional support from the 899 NIHR Oxford BRC. The University of Cambridge has received salary support for M.L.E. through 900 the National Health Service in the East of England through the Clinical Academic Reserve. The 901 views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the 902 Department of Health.

903 Author contributions

L.S.W., J.A.T. and R.C.F. conceptualised this work and designed the experiments. M.L., L.G. and
R.C.F. performed the scRNA-seq experiments. J-Y.Z. led the analysis of the scRNA-seq data with
help from F.H. and D.T. M.M. and J.H.M.Y. performed the in vitro suppression experiments and
analysed the data under the supervision of T.I.M.T. M.L.P. and R.C.F. performed FACS
experiments and analysed the data. J.K., F.W-L. and M.L.E. supervised the DILfrequency study.
T.I.M.T. provided conceptual advice on the experiments. J-Y.Z., L.S.W, J.A.T. and R.C.F. wrote
the manuscript with input from all authors.

911

912 **Competing interests**

- 913 F.W-L. is employed by Vertex Pharmaceuticals; J.A.T. is a member of the GSK Human Genetics
- 914 Advisory Board. The remaining authors declare no competing interests.

915 **References**

916	1.	Koreth, J. et al. Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease. New	
917		Engl J Med 365 , 2055–2066 (2011).	
918	2.	Saadoun, D. et al. Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-	
919		Induced Vasculitis. <i>New Engl J Med</i> 365 , 2067–2077 (2011).	
920	3.	Castela, E. et al. Effects of Low-Dose Recombinant Interleukin 2 to Promote T-	
921		Regulatory Cells in Alopecia Areata. JAMA Dermatol 150, 748–751 (2014).	
922	4.	von Spee-Mayer, C. et al. Low-dose interleukin-2 selectively corrects regulatory T cell	
923		defects in patients with systemic lupus erythematosus. Ann Rheum Dis 75, 1407–1415	
924		(2016).	
925	5.	Zhao, T. X. et al. Low-dose interleukin-2 in patients with stable ischaemic heart disease	
926		and acute coronary syndromes (LILACS): protocol and study rationale for a randomised,	
927		double-blind, placebo-controlled, phase I/II clinical trial. BMJ Open 8, e022452 (2018).	
928	6.	He, J. et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus	
929		erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 79,	
930		141–149 (2020).	
931	7.	Klatzmann, D. & Abbas, A. K. The promise of low-dose interleukin-2 therapy for	
932		autoimmune and inflammatory diseases. Nat Rev Immunol 15, 283-294 (2015).	
933	8.	Graßhoff, H. et al. Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases.	
934		Front Immunol 12, e648408 (2021).	
935	9.	Kolios, A. G. A., Tsokos, G. C. & Klatzmann, D. Interleukin-2 and regulatory T cells in	
936		rheumatic diseases. Nat Rev Rheumatol 17, 749–766 (2021).	
937	10.	Ghosh, S. et al. Polygenic control of autoimmune diabetes in nonobese diabetic mice. Nat	
938		Genet 4, 404–409 (1993).	
939	11.	Todd, J. A. Etiology of Type 1 Diabetes. Immunity 32, 457-467 (2010).	
940	12.	Hulme, M. A., Wasserfall, C. H., Atkinson, M. A. & Brusko, T. M. Central Role for	
941		Interleukin-2 in Type 1 Diabetes. Diabetes 61, 14–22 (2011).	
942	13.	Yamanouchi, J. et al. Interleukin-2 gene variation impairs regulatory T cell function and	
943		causes autoimmunity. Nat Genet 39 , 329–337 (2007).	
944	14.	Tang, Q. et al. Central Role of Defective Interleukin-2 Production in the Triggering of	
945		Islet Autoimmune Destruction. Immunity 28, 687–697 (2008).	
946	15.	Hartemann, A. et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2	
947		randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 1, 295-	
948		305 (2013).	
949	16.	Rosenzwajg, M. et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell	
950		tuned milieu in T1D patients. J Autoimmun 58, 48–58 (2015).	
951	17.	Rosenzwajg, M. <i>et al.</i> Low-dose IL-2 in children with recently diagnosed type 1 diabetes:	
952		a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.	
953		Diabetologia 63 , 1808–1821 (2020).	
954	18.	Todd, J. A. J. et al. Regulatory T cell responses in participants with type 1 diabetes after a	
955		single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial.	
956		<i>PLoS Med</i> 13 , e1002139 (2016).	
 dosing in patients with type I diabetes. <i>JCI Insight</i> 3, (2018). Trzupek, D. <i>et al.</i> Single-cell multi-omics analysis roveals IFN-driven alterations in T lymphocytes and natural killer cells in systemic lupus erythematosus. <i>Wellcome Open Res</i> 6, (2021). Kenefeck, R. <i>et al.</i> Follicular helper T cell signature in type 1 diabetes. <i>J Clin Invest</i> 125, 292–303 (2015). Ferreira, R. C. <i>et al.</i> IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. <i>Diabetologia</i> 58, 781–790 (2015). Ekman, I. <i>et al.</i> Circulating CXCR5–PD-11i peripheral T helper cells are associated with progression to type 1 diabetes. <i>Diabetologia</i> 62, 1681–1688 (2019). von Herrath, M. <i>et al.</i> Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes. <i>Tology</i> 212–224 (2021). Bell, C. J. M. <i>et al.</i> Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>J Autoimmun</i> 56, 66–80 (2015). Yu, A. <i>et al.</i> Slecetive IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. <i>Diabetes</i> 64, 2172–2183 (2015). Trzupek, D. <i>et al.</i> Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). Ito, S. <i>et al.</i> Ultra-low Dose Interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-cent phase 1 and 2a clinical trial. <i>Lancet Rheumatol</i> 1, e44–e54 (2019). Uxa, S. <i>et al.</i> Liow-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-cent phase 1 and 2a clinical trial. <i>Lancet Rheumatol</i> 1, e44–e54 (2019). di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or N	957	19.	Seelig, E. et al. The DIL frequency study is an adaptive trial to identify optimal IL-2
--	-------------	-----	---
 Trzupek, D. <i>et al.</i> Single-cell multi-omics analysis reveals IFN-driven alterations in T lymphocytes and natural killer cells in systemic lupus crythematosus. <i>Wellcome Open Res</i> 6, (2021). Kenefeck, R. <i>et al.</i> Follicular helper T cell signature in type 1 diabetes. <i>J Clin Invest</i> 125, 292–303 (2015). Ferreira, R. C. <i>et al.</i> IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. <i>Diabetologia</i> 58, 781–790 (2015). Ekman, I. <i>et al.</i> Circulating CXCR5–PD-1hi peripheral T helper cells are associated with progression to type 1 diabetes. <i>Diabetologia</i> 62, 1681–1688 (2019). von Herrath, M. <i>et al.</i> Anti-interclukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes Endocrinol</i> 9, 212–224 (2021). Bell, C. J. M. <i>et al.</i> Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>J Autoimmun</i> 56, 66–80 (2015). Yu, A. <i>et al.</i> Sclective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. <i>Diabetes</i> 64, 2172–2183 (2015). Trzupek, D. <i>et al.</i> Ultra-low Dose Interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet Regulatory</i> T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388– 1395 (2014). Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). di Rosa, R., Cossarizza, A., & Hayday, A. C. To K ior Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). Muño-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of Sc2/	958		dosing in patients with type 1 diabetes. JCI Insight 3, (2018).
 960 Jymphocytes and natural killer cells in systemic lupus erythematosus. <i>Wellcome Open Res</i> 6, (2021). 961 6, (2021). 962 21. Kenefeck, R. <i>et al.</i> Follicular helper T cell signature in type 1 diabetes. <i>J Clin Invest</i> 125, 292–303 (2015). 964 92. Ferreira, R. C. <i>et al.</i> IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. <i>Diabetologia</i> 58, 781–790 (2015). 967 93. Ekman, I. <i>et al.</i> Circulating CXCR5–PD-1hi peripheral T helper cells are associated with progression to type 1 diabetes. <i>Diabetologia</i> 62, 1681–1688 (2019). 969 94. von Herrath, M. <i>et al.</i> Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes Endocrinol</i> 9, 212–224 (2021). 971 92. Bell, C. J. M. <i>et al.</i> Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>J Autoimum</i> 56, 66–80 (2015). 977 97. Trzupek, D. <i>et al.</i> Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). 978 92. Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet Rheumatol</i> 1, 44–654 (2019). 983 93. Uxa, S. <i>et al.</i> Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). 984 94. Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmunal</i> 112, 102466 (2020). 987 94. At <i>et al.</i> Li-2 nece expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). 988 95. Gotta, J. Y. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmuna</i> 112, 102466 (2020).	959	20.	Trzupek, D. et al. Single-cell multi-omics analysis reveals IFN-driven alterations in T
 6. (2021). Kenefeck, R. <i>et al.</i> Follicular helper T cell signature in type 1 diabetes. <i>J Clin Invest</i> 125, 292–303 (2015). Ferreira, R. C. <i>et al.</i> IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. <i>Diabetologia</i> 58, 781–790 (2015). Ekman, I. <i>et al.</i> Circulating CXCR5–PD-1hi peripheral T helper cells are associated with progression to type 1 diabetes. <i>Diabetologia</i> 62, 1681–1688 (2019). von Herrath, M. <i>et al.</i> Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes Endocrinol</i> 9, 212–224 (2021). Bell, C. J. M. <i>et al.</i> Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>J Autoimmun</i> 56, 66–80 (2015). Yu, A. <i>et al.</i> Sleetive IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. <i>Diabetes</i> 64, 2172–2183 (2015). Trzupek, D. <i>et al.</i> Discovery of CD80 and CD86 as recent activation markers on regulatory T cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388–1395 (2014). Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388–1395 (2014). Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). Ariel, A. <i>et </i>	960		lymphocytes and natural killer cells in systemic lupus erythematosus. Wellcome Open Res
 Kenefeck, R. <i>et al.</i> Follicular helper T cell signature in type 1 diabetes. <i>J Clin Invest</i> 125, 292–303 (2015). Ferreira, R. C. <i>et al.</i> IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. <i>Diabetologia</i> 58, 781–790 (2015). Ekman, I. <i>et al.</i> Circulating CXCR5–PD-1hi peripheral T helper cells are associated with progression to type 1 diabetes. <i>Diabetologia</i> 62, 1681–1688 (2019). von Herrath, M. <i>et al.</i> Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet DiabeteS Endocrinol</i> 9, 212–224 (2021). Bell, C. J. M. <i>et al.</i> Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>J Autoimmun</i> 56, 66–80 (2015). Yu, A. <i>et al.</i> Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>J Autoimmun</i> 56, 66–80 (2015). Yu, A. <i>et al.</i> Sustained in vivo signaling by long-lived IL-2 induces prolonged increases 64, 2172–2183 (2015). Trzupek, D. <i>et al.</i> Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). Ito, S. <i>et al.</i> Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388–1395 (2014). Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus crythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet Rheumatol</i> 1, e44–e54 (2019). di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). di Rosa, F., Cossariz	961		6 , (2021).
 222–303 (2015). 224. Ferreira, R. C. <i>et al.</i> IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. <i>Diabetologia</i> 58, 781–790 (2015). 23. Ekman, I. <i>et al.</i> Circulating CXCR5–PD-1hi peripheral T helper cells are associated with progression to type 1 diabetes. <i>Diabetologia</i> 62, 1681–1688 (2019). 24. von Herrath, M. <i>et al.</i> Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: <i>a randomised.</i> double-blind, placebc-controlled, phase 2 trial. <i>Lancet Diabetes Endocrinol</i> 9, 212–224 (2021). 25. Bell, C. J. M. <i>et al.</i> Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>J Autoimmun</i> 56, 66–80 (2015). 26. Yu, <i>A. et al.</i> Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Thrrapy in Type 1 Diabetes. <i>Diabetes</i> 64, 2172–2183 (2015). 27. Trzupek, D. <i>et al.</i> Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). 28. Ito, S. <i>et al.</i> Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388–1395 (2014). 29. Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet Rheumatol</i> 1, e44–c54 (2019). 30. Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). 31. di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T C Cell Analysis. <i>Front Immunol</i> 12, (2021). 33. Ariel, A. <i>et al.</i> TNF-α Associated with Extracellular Matrix: Inhibition of Adherence and Mi	962	21.	Kenefeck, R. et al. Follicular helper T cell signature in type 1 diabetes. J Clin Invest 125,
 Ferreira, R. C. <i>et al.</i> IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. <i>Diabetologia</i> 58, 781–790 (2015). Ekman, I. <i>et al.</i> Circulating CXCR5–PD-1hi peripheral T helper cells are associated with progression to type 1 diabetes. <i>Diabetologia</i> 62, 1681–1688 (2019). von Herrath, M. <i>et al.</i> Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes Endocrinol</i> 9, 212–224 (2021). Bell, C. J. M. <i>et al.</i> Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>J Autoimmun</i> 56, 66–80 (2015). Yu, A. <i>et al.</i> Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. <i>Diabetes</i> 64, 2172–2183 (2015). Trzupek, D. <i>et al.</i> Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). S. <i>et al.</i> Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388– 1395 (2014). Uxa, S. <i>et al.</i> Li-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). di Rosa, F. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 12, (2020). Ariel, A. <i>et al.</i> INF-α Associated with Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix: Fibroneetin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal o</i>	963		292–303 (2015).
 circulating follicular helper T cells are increased in type 1 diabetes patients. <i>Diabetologia</i> 58, 781–790 (2015). Ekman, I. <i>et al.</i> Circulating CXCR5–PD-1hi peripheral T helper cells are associated with progression to type 1 diabetes. <i>Diabetologia</i> 62, 1681–1688 (2019). von Herrath, M. <i>et al.</i> Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes Endocrinol</i> 9, 212–224 (2021). Bell, C. J. M. <i>et al.</i> Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>J Autoimmun</i> 56, 66–80 (2015). Yu, A. <i>et al.</i> Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. <i>Diabetes</i> 64, 2172–2183 (2015). Trzupek, D. <i>et al.</i> Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). Io, S. <i>et al.</i> Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388–1395 (2014). Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus crythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet Rheumatol</i> 1, e44–e54 (2019). Uxa, S. <i>et al.</i> Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). Miñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmunol</i> 12, (2021). Ariel, A. <i>et al.</i> IL-2 Induces T Cell Analysis. <i>Front Immunol</i> 12, 6200. Ariel, A. <i>et al.</i> IL-2 Induces T Cell Analysis. <i>Front Immunol</i> 12, 6201. Kried (1, 2465 (1998). Franitza, S. <i>et al.</i>	964	22.	Ferreira, R. C. et al. IL-21 production by CD4+ effector T cells and frequency of
 58, 781–790 (2015). 23. Ekman, I. <i>et al.</i> Circulating CXCR5–PD-1hi peripheral T helper cells are associated with progression to type 1 diabetes. <i>Diabetologia</i> 62, 1681–1688 (2019). 24. von Herrath, M. <i>et al.</i> Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes Endocrinol</i> 9, 212–224 (2021). 25. Bell, C. J. M. <i>et al.</i> Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>J Autoimmun</i> 56, 66–80 (2015). 26. Yu, A. <i>et al.</i> Stelective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. <i>Diabetes</i> 64, 2172–2183 (2015). 27. Trzupek, D. <i>et al.</i> Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). 29. Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet Rheumatol</i> 1, e44–e54 (2019). 29. Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet Rheumatol</i> 1, e44–e54 (2019). 20. Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). 31. dirack, K. <i>et al.</i> Tracking immunodynamics by identification of S-G/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 112, 10246 (2020). 33. Ariel, A. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunol</i> 170, 5470 (2003). 34. Franitza, S. <i>et al.</i> TNF-α Associated with Extracellula	965		circulating follicular helper T cells are increased in type 1 diabetes patients. Diabetologia
 Ekman, I. <i>et al.</i> Circulating CXCR5–PD-1hi peripheral T helper cells are associated with progression to type 1 diabetes. <i>Diabetologia</i> 62, 1681–1688 (2019). von Herrath, M. <i>et al.</i> Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes Endocrinol</i> 9, 212–224 (2021). Bell, C. J. M. <i>et al.</i> Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>J Autoimmun</i> 56, 66–80 (2015). Yu, A. <i>et al.</i> Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. <i>Diabetes</i> 64, 2172–2183 (2015). Trzupek, D. <i>et al.</i> Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). Ito, S. <i>et al.</i> Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388– 1395 (2014). Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet Rheumatol</i> 1, e44–e54 (2019). Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). Franitza, S. <i>et al.</i> TNF-a Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T	966		58 , 781–790 (2015).
 progression to type 1 diabetes. <i>Diabetologia</i> 62, 1681–1688 (2019). von Herrath, M. <i>et al.</i> Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes Endocrinol</i> 9, 212–224 (2021). Bell, C. J. M. <i>et al.</i> Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>J Autoimmun</i> 56, 66–80 (2015). Yu, A. <i>et al.</i> Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. <i>Diabetes</i> 64, 2172–2183 (2015). Trzupek, D. <i>et al.</i> Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). Ito, S. <i>et al.</i> Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388– 1395 (2014). Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet Rheumatol</i> 1, e44–e54 (2019). Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). Franitza, S. <i>et al.</i> TNF-a Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunol</i> 15, 2738– 2747 (2000). <l< td=""><td>967</td><td>23.</td><td>Ekman, I. et al. Circulating CXCR5-PD-1hi peripheral T helper cells are associated with</td></l<>	967	23.	Ekman, I. et al. Circulating CXCR5-PD-1hi peripheral T helper cells are associated with
 von Herrath, M. <i>et al.</i> Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes Endocrinol</i> 9, 212–224 (2021). Bell, C. J. M. <i>et al.</i> Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>J Autoimmun</i> 56, 66–80 (2015). Yu, A. <i>et al.</i> Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanism Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. <i>Diabetes</i> 64, 2172–2183 (2015). Trzupek, D. <i>et al.</i> Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). Ito, S. <i>et al.</i> Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388– 1395 (2014). Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet Rheumatol</i> 1, e44–e54 (2019). Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunology</i> 165, 2738– 2747 (2000). Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Contro	968		progression to type 1 diabetes. Diabetologia 62, 1681–1688 (2019).
 β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes Endocrinol</i> 9, 212–224 (2021). Bell, C. J. M. <i>et al.</i> Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>J Autoimmun</i> 56, 66–80 (2015). Yu, A. <i>et al.</i> Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. <i>Diabetes</i> 64, 2172–2183 (2015). Trzupek, D. <i>et al.</i> Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). Ito, S. <i>et al.</i> Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388–1395 (2014). Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet Rheumatol</i> 1, e44–e54 (2019). Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). Ariel, A. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunology</i> 165, 2738–2747 (2000). Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin	969	24.	von Herrath, M. et al. Anti-interleukin-21 antibody and liraglutide for the preservation of
 placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 9, 212–224 (2021). Bell, C. J. M. et al. Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. J Autoimmun 56, 66–80 (2015). Yu, A. et al. Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. Diabetes 64, 2172–2183 (2015). Trzupek, D. et al. Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. Genome Med 12, 55 (2020). Ito, S. et al. Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. Mol Ther 22, 1388–1395 (2014). Humrich, J. Y. et al. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet Rheumatol 1, e44–e54 (2019). Uxa, S. et al. Ki-67 gene expression. Cell Death Differ 28, 3357–3370 (2021). di Rosa, F., Cossarizza, A. & Hayday, A. C. To K ior Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. Front Immunol 12, (2021). Muñoz-Ruiz, M. et al. Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. J Autoimmun 112, 102466 (2020). Ariel, A. et al. IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. J Immunol 161, 2465 (1998). Franitza, S. et al. TNF-a Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. The Journal of Immunol 27, (203). Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. J Immunol 170, 5470 (2003). Wirenshall, L. E., Clabaugh, S. E.	970		β -cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind,
 Bell, C. J. M. <i>et al.</i> Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>J Autoimmun</i> 56, 66–80 (2015). Yu, A. <i>et al.</i> Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. <i>Diabetes</i> 64, 2172–2183 (2015). Trzupek, D. <i>et al.</i> Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). Ito, S. <i>et al.</i> Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388– 1395 (2014). Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet Rheumatol</i> 1, e44–e54 (2019). Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). Ariel, A. <i>et al.</i> INF-α Associated with Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunol</i> 170, 5470 (2003). Wirenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). Miller, J. D., Clabaugh, S. E., Smith	971		placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 9, 212–224 (2021).
 973 increases of regulatory T cells. <i>J Autoimmun</i> 56, 66–80 (2015). 974 26. Yu, A. <i>et al.</i> Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple 975 Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. 976 <i>Diabetes</i> 64, 2172–2183 (2015). 977 27. Trzupek, D. <i>et al.</i> Discovery of CD80 and CD86 as recent activation markers on 978 regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). 979 28. Ito, S. <i>et al.</i> Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of 980 Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388– 1395 (2014). 982 29. Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus 983 erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet 984 Rheumatol</i> 1, e44–e54 (2019). 985 30. Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). 986 31. di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use 987 and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). 988 32. Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T 989 cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). 930 34. Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix: Inhibition of 994 Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 995 161, 2465 (1998). 933 34. Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop 994 Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunology</i> 165, 2738– 2747 (2000). 953 35. Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and 997 (2003). 936. Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present i	972	25.	Bell, C. J. M. et al. Sustained in vivo signaling by long-lived IL-2 induces prolonged
 Yu, A. <i>et al.</i> Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. <i>Diabetes</i> 64, 2172–2183 (2015). Trzupek, D. <i>et al.</i> Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). Ito, S. <i>et al.</i> Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388– 1395 (2014). Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet</i> <i>Rheumatol</i> 1, e44–e54 (2019). Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). Ariel, A. <i>et al.</i> INF-α Associated with Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunology</i> 165, 2738– 2747 (2000). Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol </i>	973		increases of regulatory T cells. J Autoimmun 56, 66-80 (2015).
 975 Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. <i>Diabetes</i> 64, 2172–2183 (2015). 977 27. Trzupek, D. <i>et al.</i> Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). 979 28. Ito, S. <i>et al.</i> Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388– 1395 (2014). 982 29. Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet</i> <i>Rheumatol</i> 1, e44–e54 (2019). 985 30. Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). 986 31. di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). 987 29. Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). 990 33. Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). 993 34. Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunol</i> 170, 5470 (2003). 996 35. Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). 999 36. Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	974	26.	Yu, A. et al. Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple
 Diabetes 64, 2172–2183 (2015). Trzupek, D. et al. Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). Ito, S. et al. Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388– 1395 (2014). Humrich, J. Y. et al. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet</i> <i>Rheumatol</i> 1, e44–e54 (2019). Uxa, S. et al. Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). Muñoz-Ruiz, M. et al. Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). Ariel, A. et al. IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). Franitza, S. et al. TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunol</i> 170, 5470 (2003). Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	975		Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes.
 Trzupek, D. <i>et al.</i> Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). Ito, S. <i>et al.</i> Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388– 1395 (2014). Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet</i> <i>Rheumatol</i> 1, e44–e54 (2019). Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunol</i> 170, 5470 (2003). Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	976		<i>Diabetes</i> 64, 2172–2183 (2015).
 978 regulatory T cells by protein-RNA single-cell analysis. <i>Genome Med</i> 12, 55 (2020). 979 28. Ito, S. <i>et al.</i> Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of 980 Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388– 1395 (2014). 981 1395 (2014). 982 29. Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus 983 erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet</i> 984 <i>Rheumatol</i> 1, e44–e54 (2019). 985 30. Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). 986 31. di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use 987 and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). 988 32. Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T 990 cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). 990 33. Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of 991 Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 992 161, 2465 (1998). 993 34. Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop 994 Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunol</i> 170, 5470 996 35. Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and 997 Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 998 36. Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 997 2 is present in human blood vessels and released in biologically active form by 998 1001 heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	977	27.	Trzupek, D. et al. Discovery of CD80 and CD86 as recent activation markers on
 Ito, S. <i>et al.</i> Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388– 1395 (2014). Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet</i> <i>Rheumatol</i> 1, e44–e54 (2019). Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunol</i> 170, 5470 (2003). Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	978		regulatory T cells by protein-RNA single-cell analysis. Genome Med 12, 55 (2020).
980Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. Mol Ther 22, 1388–9811395 (2014).98229.983erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet984Rheumatol 1, e44–e54 (2019).98530.98631.987di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use988and Potentials of Ki-67 for T Cell Analysis. Front Immunol 12, (2021).98832.98932.980Muñoz-Ruiz, M. et al. Tracking immunodynamics by identification of S-G2/M-phase T989cells in human peripheral blood. J Autoimmun 112, 102466 (2020).98033.981Ariel, A. et al. IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of981Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. J Immunol992161, 2465 (1998).99334.994Franitza, S. et al. TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop994Signal for Chemotactically Migrating T Cells. The Journal of Immunology 165, 2738–974(2000).99635.997Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and998Control of T Cell Responses by Heparan Sulfate-Bound IL-2. J Immunol 170, 54709982003).99936.999Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin-99926999<	979	28.	Ito, S. et al. Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of
 1395 (2014). Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet</i> <i>Rheumatol</i> 1, e44–e54 (2019). Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunology</i> 165, 2738– 2747 (2000). Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	980		Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Mol Ther</i> 22, 1388–
 P82 29. Humrich, J. Y. <i>et al.</i> Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet</i> <i>Rheumatol</i> 1, e44–e54 (2019). 985 30. Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). 986 31. di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). 987 983 98. 988 32. Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). 990 33. Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). 993 34. Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunology</i> 165, 2738– 2747 (2000). 996 35. Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). 999 36. Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	981		1395 (2014).
 erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. <i>Lancet</i> <i>Rheumatol</i> 1, e44–e54 (2019). 30. Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). 31. di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). 32. Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). 33. Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). 34. Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunology</i> 165, 2738– 2747 (2000). 35. Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). 36. Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	982	29.	Humrich, J. Y. et al. Low-dose interleukin-2 therapy in refractory systemic lupus
 <i>Rheumatol</i> 1, e44–e54 (2019). 30. Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). 31. di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). 32. Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). 33. Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). 34. Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunology</i> 165, 2738– 2747 (2000). 35. Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). 36. Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	983		erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet
 30. Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28, 3357–3370 (2021). 31. di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). 32. Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). 33. Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). 34. Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunology</i> 165, 2738– 2747 (2000). 35. Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). 36. Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	984		<i>Rheumatol</i> 1, e44–e54 (2019).
 di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunology</i> 165, 2738– 2747 (2000). Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	985	30.	Uxa, S. <i>et al.</i> Ki-67 gene expression. <i>Cell Death Differ</i> 28 , 3357–3370 (2021).
 and Potentials of Ki-67 for T Cell Analysis. <i>Front Immunol</i> 12, (2021). 32. Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). 33. Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). 34. Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunology</i> 165, 2738–2747 (2000). 35. Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). 36. Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin-2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	986	31.	di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use
 Muñoz-Ruiz, M. <i>et al.</i> Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunol</i> 165, 2738–2747 (2000). Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin-2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	987	~ ~	and Potentials of K1-67 for T Cell Analysis. Front Immunol 12, (2021).
 cells in human peripheral blood. <i>J Autoimmun</i> 112, 102466 (2020). 33. Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). 34. Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunology</i> 165, 2738– 2747 (2000). 35. Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). 36. Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	988	32.	Muñoz-Ruiz, M. et al. Tracking immunodynamics by identification of S-G2/M-phase T
 Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunology</i> 165, 2738– 2747 (2000). Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	989	22	cells in human peripheral blood. J Autoimmun 112, 102466 (2020).
 Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i> 161, 2465 (1998). 34. Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunology</i> 165, 2738– 2747 (2000). 35. Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). 36. Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	990	33.	Ariel, A. <i>et al.</i> IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of
 992 161, 2465 (1998). 993 34. Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunology</i> 165, 2738–2747 (2000). 996 35. Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). 999 36. Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin-2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	991		Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. <i>J Immunol</i>
 993 34. Franitza, S. <i>et al.</i> TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop 994 Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunology</i> 165, 2738– 995 2747 (2000). 996 35. Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and 997 Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 998 (2003). 999 36. Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	992	~ 1	161 , 2465 (1998).
 Signal for Chemotactically Migrating T Cells. <i>The Journal of Immunology</i> 165, 2738–2747 (2000). Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin-2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	993	34.	Franitza, S. <i>et al.</i> TNF- α Associated with Extracellular Matrix Fibronectin Provides a Stop
 2747 (2000). 35. Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). 36. Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	994		Signal for Chemotactically Migrating T Cells. The Journal of Immunology 165, 2/38–
 Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. <i>J Immunol</i> 170, 5470 (2003). Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	995	2.5	$2^{7}4^{7}$ (2000).
 Control of T Cell Responses by Heparan Sulfate-Bound IL-2. J Immunol 170, 5470 (2003). 36. Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin-2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	996	35.	Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and
 (2003). 36. Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	997		Control of T Cell Responses by Heparan Sulfate-Bound IL-2. J Immunol 170, 5470
 Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin- 2 is present in human blood vessels and released in biologically active form by heparanase. <i>Immunol Cell Biol</i> 90, 159–167 (2012). 	998	26	
10002 is present in numan blood vessels and released in biologically active form by1001heparanase. Immunol Cell Biol 90, 159–167 (2012).	999 1000	36.	Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin-
$1001 \qquad \text{neparanase. Immunol Cell Biol 90, 159–16/ (2012).}$	1000		2 is present in numan blood vessels and released in biologically active form by
	1001		neparanase. <i>Immunoi Cell Biol</i> 90, 139–16/ (2012).

1002	37.	Ferreira, R. C. et al. Cells with Treg-specific FOXP3 demethylation but low CD25 are
1003		prevalent in autoimmunity. J Autoimmun 84, 75–86 (2017).
1004	38.	Singh, S. S. et al. Amphiregulin in cellular physiology, health, and disease: Potential use
1005		as a biomarker and therapeutic target. J Cell Physiol 237, 1143–1156 (2022).
1006	39.	West, N. R. et al. Oncostatin M drives intestinal inflammation and predicts response to
1007		tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.
1008		Nat Med 23, 579–589 (2017).
1009	40.	Richard, A. C. et al. Targeted genomic analysis reveals widespread autoimmune disease
1010		association with regulatory variants in the TNF superfamily cytokine signalling network.
1011		<i>Genome Med</i> 8 , 76 (2016).
1012	41.	Maña, P. et al. LIGHT (TNFSF14/CD258) Is a Decisive Factor for Recovery from
1013		Experimental Autoimmune Encephalomyelitis. J Immunol 191, 154–163 (2013).
1014	42.	Ahern, D. J. et al. A blood atlas of COVID-19 defines hallmarks of disease severity and
1015		specificity. Cell 185, 916-938 (2022).
1016	43.	Su, Y. et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 185,
1017		881-895.e20 (2022).
1018	44.	Whangbo, J. S. <i>et al.</i> Functional analysis of clinical response to low-dose IL-2 in patients
1019		with refractory chronic graft-versus-host disease. <i>Blood Adv</i> 3 , 984–994 (2019).
1020	45.	Whangbo, J. S. <i>et al.</i> Dose-escalated interleukin-2 therapy for refractory chronic graft-
1021	-	versus-host disease in adults and children. <i>Blood Adv</i> 3 , 2550–2561 (2019).
1022	46.	Bielekova, B. et al. Regulatory CD56bright natural killer cells mediate
1023		immunomodulatory effects of IL-2R α -targeted therapy (daclizumab) in multiple sclerosis.
1024		Proc Natl Acad Sci USA 103, 5941–5946 (2006).
1025	47.	Melsen, J. E., Lugthart, G., Lankester, A. C. & Schilham, M. W. Human Circulating and
1026		Tissue-Resident CD56bright Natural Killer Cell Populations. Front Immunol 7, 262
1027		(2016).
1028	48.	Ballesteros-Tato, A. et al. Interleukin-2 Inhibits Germinal Center Formation by Limiting T
1029		Follicular Helper Cell Differentiation. <i>Immunity</i> 36 , 847–856 (2012).
1030	49.	Locci, M. <i>et al.</i> Activin A programs the differentiation of human TFH cells. <i>Nat Immunol</i>
1031		17. 976–984 (2016).
1032	50.	He. J. et al. Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets
1033	000	in patients with systemic lupus ervthematosus. <i>Nat Med</i> 22, 991–993 (2016).
1034	51.	Liu, S. M. <i>et al.</i> Differential IL-21 signaling in APCs leads to disparate Th17
1035	011	differentiation in diabetes-susceptible NOD and diabetes-resistant NOD Idd3 mice. <i>J Clin</i>
1036		Invest 121 4303–4310 (2011)
1037	52	Crotty S T Follicular Helper Cell Biology: A Decade of Discovery and Diseases
1038	52.	Immunity 50 1132–1148 (2019)
1030	53	Ren H M Lukacher A E Rahman Z S M & Olsen N I New developments
1040	25.	implicating II -21 in autoimmune disease <i>I Autoimmun</i> 122 102689 (2021)
1041	54	Sage P T & Sharpe A H T follicular regulatory cells <i>Immunol Rev</i> 271 246–259
1042	51.	(2016)
1042	55	Jacobsen I et al Expression of Foxn3 by T follicular helper cells in end-stage germinal
1043	55.	centers Science 373 eabe5146 (2021)
1044	56	Provine N M & Klenerman P MAIT Cells in Health and Disease Annu Ray Immunol
1045	50.	38 203 228 (2020)
1040		30 , 203–220 (2020).

1047	57.	Tao, H. et al. Differential controls of MAIT cell effector polarization by
1048		mTORC1/mTORC2 via integrating cytokine and costimulatory signals. <i>Nat Commun</i> 12 ,
1049		2029 (2021).
1050	58.	Zhou, P. et al. Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in
1051		systemic lupus erythematosus. PLoS Pathog 17, e1009858 (2021).
1052	59.	Matsumoto, A. et al. CIS, a Cytokine Inducible SH2 Protein, is a Target of the JAK-
1053		STAT5 Pathway and Modulates STAT5 Activation. Blood 89, 3148-3154 (1997).
1054	60.	Gill, K. L., Gardner, I., Li, L. & Jamei, M. A Bottom-Up Whole-Body Physiologically
1055		Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate
1056		of Subcutaneous Absorption of Therapeutic Proteins. AAPS J 18, 156–170 (2016).
1057	61.	Bohnacker, S. et al. Mild COVID-19 imprints a long-term inflammatory eicosanoid- and
1058		chemokine memory in monocyte-derived macrophages. Mucosal Immunol (2022)
1059		doi:10.1038/s41385-021-00482-8.
1060	62.	Phetsouphanh, C. et al. Immunological dysfunction persists for 8 months following initial
1061		mild-to-moderate SARS-CoV-2 infection. Nat Immunol 23, 210-216 (2022).
1062	63.	Marcovecchio, M. L. et al. Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a
1063		phase 2, multicentre, double-blind, randomized, placebo-controlled trial. Wellcome Open
1064		<i>Res</i> 5, (2020).
1065	64.	Ferreira, R. C. et al. Chronic Immune Activation in Systemic Lupus Erythematosus and
1066		the Autoimmune PTPN22 Trp620 Risk Allele Drive the Expansion of FOXP3+
1067		Regulatory T Cells and PD-1 Expression. Front Immunol 10, 2606 (2019).
1068	65.	Sims, E. K. et al. Teplizumab improves and stabilizes beta cell function in antibody-
1069		positive high-risk individuals. Sci Transl Med 13, eabc8980 (2021).
1070	66.	Quattrin, T. et al. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1
1071		Diabetes. New Engl J Med 383, 2007–2017 (2020).
1072	67.	Dayan, C. M. et al. Preventing type 1 diabetes in childhood. Science 373, 506-510 (2021).
1073	68.	Waldron-Lynch, F. et al. Rationale and study design of the Adaptive study of IL-2 dose on
1074		regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive
1075		dose finding trial. BMJ Open 4, (2014).
1076	69.	Truman, L. A. et al. Protocol of the adaptive study of IL-2 dose frequency on regulatory T
1077		cells in type 1 diabetes (DIL frequency): a mechanistic, non-randomised, repeat dose,
1078		open-label, response-adaptive study. BMJ Open 5, (2015).
1079	70.	Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat Methods
1080		9, 357–359 (2012).
1081	71.	Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: Computational Identification of Cell
1082		Doublets in Single-Cell Transcriptomic Data. Cell Syst 8, 281-291.e9 (2019).
1083	72.	Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573-3587.e29
1084		(2021).
1085	73.	Aitchison, J. The Statistical Analysis of Compositional Data. (Chapman & Hall, Ltd.,
1086		1986).
1087	74.	McInnes, L., Healy, J. & Melville, J. UMAP: Uniform Manifold Approximation and
1088		Projection for Dimension Reduction. ArXiv arXiv:1802, (2018).
1089	75.	Blondel, V. D., Guillaume, JL., Lambiotte, R. & Lefebvre, E. Fast unfolding of
1090		communities in large networks. Journal of statistical mechanics: theory and experiment
1091		2008 , P10008 (2008).

- 109276.Itay, T. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-1093cell RNA-seq. Science 352, 189–196 (2016).
- 1094 77. Pekalski, M. L. *et al.* Postthymic expansion in human CD4 naive T cells defined by
 1095 expression of functional high-affinity IL-2 receptors. *J Immunol* 190, 2554–2566 (2013).
- 1096 78. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion
 1097 for RNA-seq data with DESeq2. *Genome Biol* 15, 1–21 (2014).
- 1098 79. Zhu, A., Ibrahim, J. G. & Love, M. I. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. *Bioinformatics* 35, 2084–2092 (2019).
- 110180.Street, K. *et al.* Slingshot: cell lineage and pseudotime inference for single-cell1102transcriptomics. *BMC Genomics* 19, 477 (2018).
- 1103 81. van den Berge, K. *et al.* Trajectory-based differential expression analysis for single-cell
 1104 sequencing data. *Nat Commun* 11, 1201 (2020).

1106 Figures



1108

Figure 1. Interval low-dose IL-2 administered every three days sustained an increased frequency
of CD4⁺ regulatory T cells and CD56^{br} NK cells in blood.

1111 **a**, Schematic representation of the interval low-dose IL-2 (iLD-IL-2) dosing regimen used in this study.

1112 **b**, Gating strategy for the delineation of the five T and NK cell populations assessed by flow cytometry.

1113 Values shown represent the average frequency of the respective immune cell population at baseline (Day

1114 0; \pm standard error of mean, SEM) of the 18 DIL frequency participants. c, Variation (depicted as the %

1115 change from baseline pre-treatment levels) in the frequency of the five assessed immune subsets in blood (denominator is total T cells for T cell subsets, CD 4⁺ T cells for the CD 4⁺ Treg subset and total CD56⁺ 1116 NK cells for NK subsets). Data shown depict the average (± SEM) variation at each visit in the 18 1117 DIL frequency participants treated with the 3-day interval dosing schedule. **d-e**. Absolute numbers of the 1118 assessed CD4⁺ CD127^{low}CD25^{hi} (Tregs) and CD56^{br} NK cell (d), as well as the broader CD4⁺ and CD8⁺ 1119 T and CD56⁺NK cell (e) subsets in blood. Data shown depict the average (\pm SEM) numbers at each visit 1120 in the 18 selected participants - treated with either 0.2 (N = 4), 0.32 (N = 12) or 0.47 (N = 2) × 10⁶ IU/m² 1121 IL-2. Dotted lines indicate the average baseline pre-treatment numbers of each immune subset. Plots 1122 1123 depicting the changes of the immune populations shown in **c-e** in each of the individual study participants are shown in ref.¹⁹. **f**, Overview of the experimental design employed in this study. Simultaneous 1124 quantification of mRNA (N = 565 probes) and surface-expressed proteins (N = 65 AbSeq antibodies) 1125 was performed at the single-cell level using the BD Rhapsody system and employing a cell-enrichment 1126 strategy. Equal proportions of flow-sorted cells subsets (30% CD4⁺ Tregs; 25% CD4⁺ Tconv and CD8⁺ 1127 T; 12% CD56^{br} NK and 8% CD56^{dim} NK cells) from 13 selected DIL frequency participants treated with 1128 1129 the 3-day dosing interval were profiled at three distinct time points: (i) prior to IL-2 treatment (Day 0), (ii) three days after the penultimate dose of IL-2 (Day 27), and (iii) one month after the last dose of IL-1130 1131 2 (Day 55). g. Uniform Manifold Approximation and Projection (UMAP) plot depicting the 15 clusters 1132 identified from the clustering of the 482,531 unstimulated cells profiled in this study. Clusters were 1133 manually annotated based on the expression of key differentially expressed mRNA and protein markers. Light grey cells correspond to CD56^{br} NK cells without sorting gate information. 1134



1137

1138 Figure 2. Interval low-dose IL-2 immunotherapy selectively expands FOXP3⁺HELIOS⁺ Tregs.

a, UMAP plot depicting the 13 clusters identified from the clustering of the 149,202 unstimulated cells 1139 1140 sorted from the CD127^{low}CD25^{hi} Treg gate profiled in this study. Clusters were manually annotated 1141 based on the expression of key differentially expressed mRNA and protein markers. Clusters corresponding to: (i) naïve Tregs (defined as CD45RA⁺ FOXP3⁺HELIOS⁺); (ii) memory Tregs (defined 1142 as CD45RA⁻ FOXP3⁺HELIOS⁺); or (iii) CD25⁺ FOXP3⁻HELIOS⁻ Teffs (defined as CD45RA⁻ FOXP3⁻ 1143 HELIOS⁻) are annotated in green, blue and red, respectively. All other miscellaneous clusters not 1144 conforming to this definition are annotated in black. b, Relative frequency changes of naïve 1145 FOXP3⁺HELIOS⁺ Tregs, memory FOXP3⁺HELIOS⁺ Tregs, and CD25⁺ FOXP3⁻HELIOS⁻ Teffs 1146 clusters on Day 27 compared to the baseline pre-treatment (Day 0) levels, for unstimulated cells. Relative 1147 frequency of a certain cluster was calculated as the number of cells in that cluster divided by the total 1148

number of cells sorted from the Treg gate. c,d Corresponding UMAP plot (c) and relative frequency for 1149 1150 the identified subsets (d) for the 115,153 in vitro stimulated CD4⁺ T cells sorted from the 1151 CD127^{low}CD25^{hi} Treg gate. e, Absolute cell numbers of naïve FOXP3⁺HELIOS⁺ Tregs, memory 1152 FOXP3⁺HELIOS⁺ Tregs, and CD25⁺ FOXP3⁻HELIOS⁻ Teffs on Day 0, Day 27 and Day 35, for 1153 unstimulated (circles connected by solid lines) and stimulated (triangles connected by dashed lines) cells. 1154 Absolute cell numbers were calculated as the total absolute number of Tregs measured by FACS 1155 multiplied by the relative frequency of a certain cluster. f, Per-cell Treg suppression efficiency for each time point. Treg suppression efficiency was assessed in vitro by culturing CD4⁺CD25^{hi}CD127^{low} Tregs 1156 1157 with autologous CD4⁺CD25^{-/low}CD127⁺ Teffs at various ratios (x axis) and represented as the decrease in Teff proliferation compared with the control condition (y axis). PBMCs from 12 participants sampled 1158 1159 on Day 0, Day 24 and Day 55 were used for this assay. *FDR-adjusted P < 0.05; two-sided Wilcoxon signed-rank test comparing the relative frequency of the subsets between Day 27 and Day 0. In b, d and 1160 1161 f, each dot represents cells from a single participant. Dots with the same colour represent the same 1162 participant.



1165

1166 Figure 3. Low-dose IL-2 treatment inhibits the differentiation of IL-21-producing CD4⁺ T cells

1167 **a**, Expression levels of 30 differentially expressed markers in the four assessed IL-21-producing CD4⁺ 1168 T cell subsets from *in vitro* stimulated CD4⁺ T cells: CXCR5⁺ T_{CM} and CXCR5^{low}IL-21⁺ sorted from

- 1169 the CD25^{-/low} Tconv gate; and CD25⁺ T_{FH} and CD25⁺IL-21⁺ T_{FH} sorted from the CD127^{low}CD25^{hi} Treg
- 1170 gate. Expression levels are based on normalised and scaled single-cell expression data. Gene markers

were selected based on pairwise differential expression analysis among the four assessed clusters. **b**, 1171 1172 Expression of CXCR5 (AbSeq) and IL21 in the four assessed IL-21⁺ CD4⁺ T cell subsets from in vitro stimulated cells. c, UMAP plot depicting the clustering of *in vitro* stimulated CD4⁺ T cells (N = 209,5431173 1174 cells). Cells are coloured according to the respective IL-21⁺ cluster assignment. Dark grey and light grey denote cells sorted from the CD127^{low}CD25^{hi} Treg gate and CD25^{-/low} Tconv gate, respectively, that are 1175 not in IL-21⁺ clusters (c); or by normalised and scaled IL-21 expression levels (d). e, Gene expression 1176 1177 changes between IL-21⁺ and IL-21⁻ cells within each of the four assessed IL-21⁺ CD4⁺ T cell clusters. Fold change values were calculated from pseudo-bulk expression data. Genes with absolute log₂ fold 1178 1179 change values equal to or greater than 1.2 and FDR-adjusted P values less than 0.01 in at least one cluster were selected. **f**, Relative frequency changes of $IL-21^+$ cells within the two CD4⁺ T cell subsets 1180 1181 displaying higher expression levels of IL-21: the CXCR5^{low}IL-21⁺ subset (left panel) and the CD25⁺IL-21⁺ T_{FH} subset (right panel), comparing Day 27 and Day 55 with Day 0, respectively. Each dot represents 1182 1183 cells from a single participant. Dots with the same colour represent the same participant. P values were 1184 calculated by comparing the relative frequency values between the two time points using a two-sided 1185 Wilcoxon signed-rank test.



1188

1189 Figure 4. IL-2 treatment reduces the frequency of innate-like CD8⁺ MAIT and $V_{\gamma9}V_{\delta2}$ T cells in 1190 circulation and selectively expands the IL-2 sensitive CD56^{br} NK cell subset.

1191 **a**, UMAP plot depicting the clustering of the 93,379 unstimulated CD8⁺ T cells profiled in this study.

1192 Clusters were manually annotated based on the expression of key differentially expressed mRNA and

1193 protein markers. **b**, Relative frequency changes of five selected CD8⁺ T cell clusters on Day 27 compared

to the baseline pre-treatment (Day 0) levels, for unstimulated cells. c, Relative frequency of the innate-1194 like mucosal-associated invariant T cell (MAIT; left panel) and $V_{\nu 9}V_{\delta 2}$ T cell (right panel) clusters on 1195 1196 Day 0, Day 27, and Day 55. Each line represents cells from a participant. Lines with the same colour 1197 represent the same participant. d, UMAP plot depicting the clustering of the 118,625 unstimulated NK 1198 cells profiled in this study. Clusters were manually annotated based on the expression of key differentially expressed mRNA and protein markers. e, UMAP plot as in d, split and coloured by FACS 1199 sorting gates of origin. **f-g**, Relative frequency changes of five selected CD56^{br} (**f**) or CD56^{dim} (**g**) NK 1200 cell clusters on Day 27 compared to the baseline pre-treatment (Day 0) levels, for unstimulated cells. 1201 "CD56^{dim} cells sorted as CD56^{br}" represents the fraction of cells sorted from the CD56^{br} NK cell gate 1202 that are found in clusters that predominantly consists of CD56^{dim} NK cells (ie. Clusters 0 and 3). 1203 Conversely, "CD56^{br} cells sorted as CD56^{dim}" represents the fraction of cells sorted from the CD56^{dim} 1204 NK cell gate that are found in clusters that predominantly consists of CD56^{br} NK cells (ie. Clusters 1, 2 1205 1206 and 4). In **b**, **f**, and **g**, the relative frequency of a certain cluster is calculated as the number of cells in that cluster divided by the total number of cells sorted from the CD8 (b), CD56^{br} (f) or CD56^{dim} (g) NK 1207 1208 cell gate. Each dot represents cells from a single participant. Dots with the same colour represent the same participant. Asterisks denote statistically significant differences (FDR-adjusted P < 0.05; two-sided 1209 1210 Wilcoxon signed-rank test) in cell population frequencies between Day 27 and Day 0.







1216 **a-b**, Volcano plots depicting gene expression changes between Day 0 and Day 27 for the five assessed 1217 immune populations, for unstimulated (**a**) and stimulated (**b**) cells. Significantly differentially expressed 1218 genes are coloured in red (upregulated genes) or blue (downregulated genes). Names of the top five up- and 1219 downregulated genes as defined by fold change are labelled on each panel. **c**, Differential expression of 1220 Day 27 signature genes. Day 27 signature genes are defined as the 40 genes that are significantly

1221 differentially expressed in at least one cell population comparing Day 27 with Day 0. Dot colours represent 1222 \log_2 fold change between Day 0 and Day 27. Larger dots represent genes that are significantly differentially 1223 expressed in a certain cell population. Manually annotated signature gene subsets are labelled with dashed 1224 boxes.

medRxiv preprint doi: https://doi.org/10.1101/2022.04.05.22273167; this version posted October 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



1226

Figure 6. Interval low-dose IL-2 immunotherapy induces a long-lasting anti-inflammatory gene
expression signature

a, Differential expression of Day 55 signature genes. Day 55 signature genes were defined as the 41

1230 genes significantly differentially expressed in at least one cell population comparing Day 55 with Day

0. Dot colours represent log₂ fold-change between Day 0 and Day 55. Larger dots represent significantly 1231 1232 differentially expressed genes. **b**, Participant-specific differential expression in $CD8^+$ T cells comparing 1233 Day 27 (top panel) or Day 55 (bottom panel) with Day 0. Top 5 up- and downregulated genes as defined 1234 by Day 55/Day 0 fold-change in CD8⁺ T cells. Participant labels are coloured by their respective IL-2 1235 dose ($\times 10^6$ IU/m²): 0.2 (cyan), 0.32 (gray), 0.47 (purple). c, Day 55 signature scores by participant for 1236 each time point and cell type. Each participant is represented by a different colour. P values were 1237 calculated using a two-tailed paired t test comparing Day 27 or Day 55 with Day 0, respectively. d-e, Variation in the mean expression scores of Day 55 signature genes across the five major cell types (mean 1238 1239 Δ signature score) between Day 27 and Day 0 (d) and between Day 55 and Day 0 (e) for each participant.

- 1240 Participants were stratified by IL-2 dose. *P* values were calculated using linear regression. In d-e, average
- 1241 values of the Day 55 signature in all five cell types are shown for each participant.

medRxiv preprint doi: https://doi.org/10.1101/2022.04.05.22273167; this version posted October 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



Figure 7. The IL-2-induced Day 55 anti-inflammatory gene expression signature is reversed in
COVID-19 patients

a, Differential expression of the 41 identified Day 55 signature genes in COVID-19 patients. Dot colours represent \log_2 fold-change between healthy controls and community COVID-19 patients from the COMBAT study⁴². Larger dots represent significantly differentially expressed genes in a

1250 certain cell population. **b-c** Day 55 gene signature scores plotted against the time since COVID-19 symptoms in the COMBAT (b) and INCOV⁴³ (c) cohorts. The Day 55 gene signature score was 1251 based on expression levels of the 41 identified Day 55 signature genes. Each dot represents a pseudo-1252 1253 bulk sample from a certain participant and time point. Up to three longitudinal samples may 1254 originate from the same participant. COVID-19 patients were stratified according to their maximum 1255 disease severity. Dashed black lines represent smooth curves fitted by locally weighted scatterplot 1256 smoothing (LOWESS). d, Correlation between the differential expression of the Day 55 signature 1257 genes and Component 187 from the COMBAT study. Of the 1,419 genes included in Component 1258 187, a gene expression signature induced by COVID-19, 77 are also present in the target transcriptional panel used in this study. The effects of IL-2 immunotherapy and COVID-19 infection 1259 1260 on the induction of these genes are compared by correlating Component loading score (y axis) with log2 fold change (Day 55/Day 0) in the CD8 population after IL-2 treatment (x axis). The positive 1261 1262 and negative values in Component 187 loading scores represent the up- and downregulation of the 1263 corresponding gene, respectively, after COVID-19 infection. Larger dots represent genes with FDR-1264 adjusted P values < 0.01, comparing Day 55 and Day 0 expression levels. e, Enrichment of Day 55 1265 signature genes in each gene expression component reported in the COMBAT study. Each dot represents a disease-associated gene expression component in the COMBAT study. Dot sizes 1266 1267 represent the number of shared genes between a certain component and the 41 Day 55 signature 1268 genes. Only top 50 components ranked by their odds ratios of enrichment (x axis) are shown. 1269 Colours represent cluster membership as reported in the COMBAT study. Components in the same 1270 cluster are associated with diseases in a similar way. Cluster 3 is associated with all severity groups 1271 of COVID-19. f, Component 187 sample loading scores plotted against time since symptoms for 1272 COVID-19 patients. Each dot represents a patient. Patients are stratified by their maximum COVID-1273 19 severity.

1275 Supplementary Figures





a, Gating strategy for the delineation of CD4⁺ effector memory T cells (T_{EM}). **b-c**, Variation (depicted as the % change from pre-treatment baseline levels) in the frequency of CD4⁺ T_{EM} (**b**), or the ratio between CD4⁺ Tregs and T_{EM} cells (**c**) during the course of the study. Baseline levels (mean +/- SEM): CD4⁺ T_{EM}

- 1283 = 10.4% +/- 1.39; CD4⁺ Treg:T_{EM} ratio = 0.76 +/- 0.07. **d-f**, Variation (depicted as the % change from 1284 pre-treatment baseline levels) in the relative frequency of CD56^{br} NK cells within the total CD3⁻CD56⁺ 1285 NK cell gate (**d**), and in the absolute number of CD56^{br} (**e**) and CD56^{dim} (**f**) NK cells in blood during the 1286 course of the study. Baseline levels (mean +/- SEM): CD56^{br} = 6.2% +/- 0.55; CD56^{br} Number (x10⁹/L) 1287 = 0.011 +/- 0.001; CD56^{dim} Number (x10⁹/L) = 0.18 +/- 0.02. Frequencies of the assessed immune subsets 1288 were determined by flow cytometry in the 18 DILfrequency participants treated with the 3-day interval 1289 dosing schedule. Data shown depict the average (± SEM) variation of the assessed immune subsets at
- 1290 each visit and were stratified according to the IL-2 dose.



1292

1293 Supplementary Figure 2. Integration of the single-cell multiomics data.

1294 **a-b.** Uniform Manifold Approximation and Projection (UMAP) plot depicting the clustering of the 1295 460,941 unstimulated cells profiled in this study. Cells were coloured according to the corresponding oligo-conjugated barcode indicative of the respective FACS sorting gate (a), or according to the 1296 1297 participant of origin (b). Untagged cells in b (labelled as 'Tag N/A') correspond to CD56^{br} NK cells, where we observed a suboptimal sample tagging efficiency, resulting in a significant fraction (37.2% in 1298 unstimulated cells) of CD56^{br} NK cells with missing sample barcode information. c, Relative proportion 1299 1300 of cells from each individual participant in each of the flow-sorted unstimulated immune cell populations. 1301 Areas of grey circles represent total cell numbers in each immune cell population. d-e, UMAP plots 1302 depicting the clustering of the 323,839 cells profiled in this study following a short (90 min) in vitro 1303 stimulation with PMA + ionomycin. Cells were coloured according to the corresponding oligo-conjugated barcode indicative of the respective FACS sorting gate (d), or to the donor information (e). Untagged cells 1304 in panel a (labelled as 'Tag N/A') correspond to CD56^{br} NK cells, where we observed a suboptimal sample 1305

tagging efficiency resulting in a significant fraction (44.3% in the *in vitro* stimulated cells) of CD56^{br} NK
cells with missing sample barcode information. **f**, Relative proportion of cells from each individual
participant in each of the flow-sorted stimulated immune cell populations. Areas of grey circles represent

1309 total cell numbers in each immune cell population.



1312 Supplementary Figure 3. Identification of proliferating cells.

1313 **a**, UMAP plot depicting the expression of the cell-cycle signature score in each unstimulated single-cell, calculated by summarising the expression levels of 11 pre-selected genes related to cell cycle. b, 1314 1315 Frequency of proliferating cells in each immune subset identified by the single-cell multiomics analysis. 1316 Proliferating cells were defined as the proportion of cells in the identified cycling clusters from each of the 5 sorted immune populations at Days 0, 27 and 55. c-d, Frequency of Ki-67⁺ cells within each of the 1317 5 assessed immune populations in T1D patients treated with a single (DILT1D; c) or with the 3-day 1318 1319 interval dosing schedule (DILfrequency; d). Ki-67 protein levels were assessed by intracellular flow cytometry in 6 patients from the DILT1D (treated with doses ranging from 0.6-1.5 x 10^6 IU/m²) and five 1320 patients from the DIL frequency (treated with interval doses ranging from 0.2-0.32 x 10⁶ IU/m²). IL-2 1321 1322 dosing days are depicted in red in the x axis.

Unstimulated CD4+ Treg gate





1325

Supplementary Figure 4. Functional annotation of the CD4⁺ CD127^{low}CD25^{hi} T cell subsets. 1326

1327 **a-b**, Expression levels of selected differentially expressed markers delineating the functional subsets in the unstimulated (a) and *in vitro* stimulated (b) CD4⁺ T cells sorted from the CD127^{low}CD25^{hi} Treg gate. 1328 1329 The size of the dots represents the frequency of the marker in the respective cluster and the colour 1330 brightness represents the relative expression level. Protein markers (AbSeq) are shown on the left section

1331 of the plots and mRNA markers on the right section. Clusters corresponding to: (i) naïve Tregs (defined

1332 as CD45RA⁺ FOXP3⁺HELIOS⁺); (ii) memory Tregs (defined as CD45RA⁻ FOXP3⁺HELIOS⁺); or (iii)

- 1333 CD25⁺ FOXP3⁻HELIOS⁻Teffs (defined as CD45RA⁻ FOXP3⁻HELIOS⁻) are annotated in green, blue
- 1334 and red, respectively. All other miscellaneous clusters not conforming to this definition are annotated in
- 1335 black.

а	and the second second	С		Unstimulated		f		Stimulated		
				FOXPO	W750		FOXP2	INTED		
			HLA-II⁺ Tregs (1)	74.3%	46.2%	CD80+ Tregs (9)	53.9%	70.6%	18.1%	
		- 1	CD80* Tregs (7)	68.6%	50.4%	Naïve Tregs (0)	46.4%	32.6%	17.5%	
b		LL o	Mitotic Tregs (10)	70.2%	45.7%	HLA-II⁺ Tregs (1)	47.3%	68.1%	20.1%	
	A CONTRACTOR OF A		FOXP3⁺ T _{FR} (11)	65.9%	18.3%	CD73⁺ Naïve (8)	43.3%	52.0%	16.8%	
		IKZF2	Naïve Tregs (0)	61.1%	44.8%	α ₄ β ₇ * Tregs (4)	40.5%	59.4%	18.2%	
			FCRL3⁺ Tregs (5)	61.0%	51.4%	T _{H1} T _{СМ} Tregs (3)	35.3%	18.8%	20.1%	
		Ū	Apoptotic Tregs (6)	54.0%	36.5%	AP-1* Tregs (2)	31.9%	21.3%	18.0%	
d			GZMK+ T _{H1} (3)	48.4%	16.7%	T _{H17} Trees (7)	25.9%	12.5%	21.0%	
		FOXP3	T _{H17} Tregs (4)	46.7%	9.1%	CD25+	19.4%	18.7%	26.3%	
		- 1	CD25⁺ Naïve (2)	41.0%	20.9%	Г _{FH} (10) CD25⁺	18.6%	10.7%	30.3%	
е		L 0	CD25* CD103* (12)	29.8%	22.6%	Naïve (5)	18.8%	12.8%	26.1%	
			СD25⁺ Т _{ЕМ} (9)	18.1%	18.0%	IL-21+ Т _{FH} (11				
		IKZF2	CD25⁺ T _{FH} (8)	15.6%	8.1%	СD25⁺ Т _{Н2} Т _{ЕМ} (6)	12.8%	26.2%		
		- 1	Total CD4 ⁺ Teffs	3.5%	3.3%	Total CD4+ Teffs	2.1%	3.3%	36.5%	
	and a state of the	0		Normalized expression	Normalized expression		-1 U 1 2 3 Normalized expression	–1 U 1 2 3 Normalized expression	-1 0 1 2 3 Normalized expression	

1337

Supplementary Figure 5. Expression of *FOXP3*, *IKZF2* (HELIOS) and *IL2* differentiate functional CD4⁺ Treg and CD4⁺ Tconv subsets.

1340 a-b, UMAP plots depicting the expression of the canonical Treg transcription factors FOXP3 (a) and *IKZF2* (encoding HELIOS; **b**) in the unstimulated cells sorted from the CD4⁺ CD127^{low}CD25^{hi} Treg 1341 gate. c, Distribution of expression levels of FOXP3 and IKZF2 in the identified unstimulated 1342 CD127^{low}CD25^{hi} CD4⁺ T cell clusters. **d-e**, UMAP plots depicting the expression of the canonical Treg 1343 transcription factors FOXP3 (d) and IKZF2 (e) in the in vitro stimulated cells. f, Histograms depicting 1344 1345 the expression of FOXP3, IKZF2 and IL2 in the identified in vitro stimulated clusters. Clusters corresponding to: (i) naïve Tregs (defined as CD45RA⁺ FOXP3⁺HELIOS⁺); (ii) memory Tregs (defined 1346 as CD45RA⁻ FOXP3⁺HELIOS⁺); or (iii) CD25⁺ FOXP3⁻HELIOS⁻Teffs (defined as CD45RA⁻ FOXP3⁻ 1347 1348 HELIOS⁻) are annotated in green, blue and red, respectively. All other miscellaneous clusters not 1349 conforming to this definition are annotated in black.

medRxiv preprint doi: https://doi.org/10.1101/2022.04.05.22273167; this version posted October 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



1351 Supplementary Figure 6. Differential abundance analysis reveals a transient increased frequency 1352 of FOXP3⁺HELIOS⁺ Tregs following ld-IL2 treatment.

1353 **a-b**, Relative frequency changes of all the identified unstimulated (a) or *in vitro* stimulated (b) CD127^{low}CD25^{hi} T cell clusters between Day 0 and Day 27 (top panels) or Day 55 (bottom panels). 1354 1355 Clusters corresponding to: (i) naïve Tregs (defined as CD45RA⁺ FOXP3⁺HELIOS⁺), (ii) memory Tregs (defined as CD45RA⁻ FOXP3⁺HELIOS⁺), and (iii) CD25⁺ FOXP3⁻HELIOS⁻Teffs (defined as 1356 1357 CD45RA⁻ FOXP3⁻HELIOS⁻) are annotated in green, blue and red, respectively. All other miscellaneous 1358 clusters not conforming to this definition are annotated in black. Asterisks denote statistically significant 1359 differences (two-sided Wilcoxon signed-rank test) in cell population frequencies between the two time 1360 points. c-d, Relative frequency changes of unstimulated (c) or in vitro stimulated (d) naïve FOXP3⁺HELIOS⁺ Treg, memory FOXP3⁺HELIOS⁺ Treg, and CD25⁺ FOXP3⁻HELIOS⁻Teff clusters in 1361 1362 blood between Day 0 and Day 55. In a-d, each dot represents cells from a single participant. Dots with 1363 the same colour represent the same participant.



1366 Supplementary Figure 7. Analysis of circulating CD4⁺ CD25^{-/low} conventional T cells

a, UMAP plot depicting the clustering of the 108,722 unstimulated CD4⁺ T cells sorted from the CD25⁻ 1367 1368 ^{/low} Tconv gate profiled in this study. Clusters were manually annotated based on the expression of key 1369 differentially expressed mRNA and protein markers. **b**, Expression levels of selected differentially 1370 expressed markers delineating the functional subsets in the unstimulated CD4⁺ T cells sorted from the 1371 CD25^{-/low} Tconv gate. The size of the dots represents the frequency of the marker in the respective cluster 1372 and the colour brightness represents the relative expression level. Protein markers (AbSeq) are shown 1373 on the left section of the plots and mRNA markers on the right section. c, Relative frequency changes of 1374 all identified unstimulated CD4⁺ CD25^{-/low} Tconv clusters in blood at Day 27 (top panel) or Day 55 1375 (bottom panel) compared to the baseline pre-treatment (Day 0) levels. d-f, Plots corresponding to a-c, for the 93,856 in vitro stimulated CD4⁺ T cells sorted from the CD25^{-/low} Tconv gate. 1376



Supplementary Figure 8. Pseudo-time analysis reveals trajectories of Treg and T_{FH} differentiation in *in vitro* stimulated CD4⁺ T cells.

1382 a, UMAP plot depicting the Treg differentiation trajectory identified by Slingshot pseudo-time 1383 analysis. **b**, Pseudo-time distribution of cells associated with the Treg trajectory, stratified by cluster 1384 labels. c, Fitted expression curves of selected canonical Treg genes by pseudo-time. d, Pseudo-time distribution of cells associated with the Treg trajectory, stratified by time points. e, UMAP plot 1385 1386 depicting the T_{FH} differentiation trajectory identified by Slingshot pseudo-time analysis. **f**, Pseudo-1387 time distribution of cells associated with the $T_{\rm FH}$ trajectory, stratified by cluster labels. g, Fitted 1388 expression curves of selected canonical T_{FH} genes by pseudo-time. h, Pseudo-time distribution of 1389 cells associated with the T_{FH} trajectory, stratified by time points. Data from **a-h** were generated from 1390 in vitro stimulated CD4⁺ T cells.

medRxiv preprint doi: https://doi.org/10.1101/2022.04.05.22273167; this version posted October 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



1394 Supplementary Figure 9. Replication of the ratio of naïve:memory Tregs by FACS

a, Gating strategy for the delineation of the naïve (CD45RA⁺) and memory (CD45RA⁻) compartment 1395 by flow cytometry within cells sorted from the CD4⁺ CD127^{low}CD25^{hi} Treg gate. **b**, Ratio between naïve 1396 and memory cells within the CD4⁺ CD127^{low}CD25^{hi} Treg gate at the three assessed timepoints (Day 0, 1397 1398 Day 27 and Day 55). The connecting line represents the median naïve:memory ratio in the 13 participants 1399 selected for single-cell analysis at each time point. c, Variation (depicted as the % change from baseline pre-treatment levels) in the naïve:memory ratio within the CD4⁺ CD127^{low}CD25^{hi} Treg gate assessed by 1400 flow cytometry. Data shown depict the average (±SEM) variation at each visit for the 13 participants 1401 1402 selected for single-cell analysis. d, Correlation between the naïve:memory ratio within CD4⁺ CD127^{low}CD25^{hi} T cells (left panel), or the corresponding ranks (right panel), obtained from FACS data 1403 1404 (x axis) and that estimated from single-cell sequencing data (y axis). e, Correlation between the frequency of naïve (CD45RA⁺; left panel) and memory (CD45RA⁻; right panel) cells within 1405 CD127^{low}CD25^{hi} T cells obtained from FACS data (x axis) and that obtained from single-cell sequencing 1406 1407 data (y axis). In b, d and e, each dot represents a sample, with colours and shapes representing participants and time points of origin, respectively. In **d-e**, linear regression lines are shown in black, 1408 1409 and 95% confidence intervals of the regression estimate are shown in grey shades.

medRxiv preprint doi: https://doi.org/10.1101/2022.04.05.22273167; this version posted October 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



1411

1412 Supplementary Figure 10. Delineation of Treg subsets by FACS

a, Gating strategy for the delineation of the FOXP3⁺HELIOS⁺ Treg, FOXP3⁺HELIOS⁻ Treg and
CD45RA⁻ FOXP3⁻HELIOS⁻ Teff subsets by flow cytometry. b-c Variation (depicted as the % change
from baseline pre-treatment levels) in the frequency of FOXP3⁺HELIOS⁺ (blue), FOXP3⁺HELIOS⁻
(black) and CD45RA⁻ FOXP3⁻HELIOS⁻ (red) cells within the CD127^{low}CD25^{hi} gate in patients treated

1417 with a single dose (DILT1D; \mathbf{b}) or with the 3-day interval dosing schedule (DILfrequency; \mathbf{c}). Baseline levels (mean +/- SEM): (i) DILT1D: FOXP3⁺HELIOS⁺ = 71.5% +/- 1.47, FOXP3⁺HELIOS⁻ = 15.6% 1418 +/- 1.63 and CD45RA⁻ FOXP3⁻HELIOS⁻ = 4.7% +/- 0.44; (ii) DILfrequency: FOXP3⁺HELIOS⁺ = 1419 66.9% +/- 2.0, FOXP3⁺HELIOS⁻ = 19.8% +/- 1.60 and CD45RA⁻ FOXP3⁻HELIOS⁻ = 8.0% +/- 1.02. 1420 d-e, Variation (depicted as the % change from baseline pre-treatment levels) in the frequency of the 1421 FOXP3⁺HELIOS⁺ Treg, FOXP3⁺HELIOS⁻ Treg and CD45RA⁻ FOXP3⁻HELIOS⁻ Teff subsets in 1422 1423 patients treated with a single dose (d) or with the 3-day interval dosing schedule. Baseline levels (mean +/- SEM): (i) DILT1D: FOXP3⁺HELIOS⁺ = 5.0% +/- 0.54, FOXP3⁺HELIOS⁻ = 1.2% +/- 0.24 and 1424 1425 $CD45RA^{-}FOXP3^{-}HELIOS^{-} = 0.34\% + -0.06$; (ii) DIL frequency: $FOXP3^{+}HELIOS^{+} = 4.2\% + -0.44$, FOXP3⁺HELIOS⁻ = 1.3% +/- 0.22 and CD45RA⁻ FOXP3⁻HELIOS⁻ = 0.49% +/- 0.05. (e). Data were 1426 1427 generated by intracellular flow cytometry in 6 patients from the DILT1D (treated with doses ranging 1428 from 0.6-1.5 x 10^{6} IU/m²) and 5 patients from the DIL frequency (treated with interval doses ranging 1429 from $0.2-0.32 \ge 10^6 \text{ IU/m}^2$). IL-2 dosing days are depicted in red in the x axis.


Supplementary Figure 11. Interval low-dose IL-2 treatment does not affect the frequency of CD25⁻ ^{/low} FOXP3⁺ T cells

1434 a, Identification of FOXP3⁺ within cells sorted from the CD25^{-/low} Tconv gate. FOXP3⁺ cells were 1435 defined as cells with one or more counts of FOXP3 RNA detected. Data was generated from the analysis 1436 of the 13 DIL frequency donors selected for the single-cell multiomics analysis. b, Box and whiskers plot depicts the frequency of FOXP3⁺ cells within the CD25^{-/low} Tconv gate at Days 0, 27 and 55. Each dot 1437 1438 represents a sample, with colours and shapes representing participants and time points of origin, respectively. c, Gating strategy for the delineation of CD25^{-/low} FOXP3⁺ T cells by flow cytometry. d-e 1439 1440 Frequency of CD25^{-/low} FOXP3⁺ T cells in patients treated with a single dose (DILT1D; **d**) or with the 1441 3-day interval dosing schedule (DIL frequency; e). f-g, Variation (depicted as the % change from baseline pre-treatment levels) in the frequency of the CD25^{-/low} FOXP3⁺T cells in patients treated with a single 1442 dose (f) or with the 3-day interval dosing schedule (g). Data were generated by intracellular flow 1443 cytometry in six patients from the DILT1D (treated with doses ranging from 0.6-1.5 x 10^6 IU/m²) and 1444 patients from the DIL frequency (treated with interval doses ranging from 0.2-0.32 x 10⁶ IU/m²). IL-2 1445 dosing days are depicted in red in the x axis. 1446



1449

1450 Supplementary Figure 12. Functional annotation of CD8⁺ T cells.

a, Expression of selected differentially-expressed markers delineating the functional subsets identified 1451 from the 13 clustering of the 93,621 unstimulated CD8⁺ T cells profiled in this study. The size of the 1452 1453 dots represents the frequency of the marker in the respective cluster and the colour brightness represents 1454 the relative expression level. Protein markers (AbSeq) are shown on the left section of the plots and 1455 mRNA markers on the right section. **b**, Relative frequency changes of all identified CD8⁺ T cell clusters 1456 on Day 27 (top panel) or Day 55 (bottom panel) compared to the baseline pre-treatment levels. c, UMAP 1457 plot depicting the clustering of in vitro stimulated CD8⁺ T cells. Clusters were manually annotated based 1458 on the expression of key differentially expressed mRNA and protein markers. d, Relative frequency 1459 changes of the 14 identified stimulated CD8⁺ T cell clusters at Day 27 compared to the baseline pre-1460 treatment (Day 0) levels.



1463 Supplementary Figure 13. Functional annotation of CD56⁺ NK cells.

a, Expression of selected differentially-expressed markers delineating the five functional subsets 1464 identified from the clustering of the 99,169 unstimulated CD56⁺ NK cells profiled in this study. The size 1465 of the dots represents the frequency of the marker in the respective cluster and the colour brightness 1466 1467 represents the relative expression level. Protein markers (AbSeq) are shown on the left section of the 1468 plots and mRNA markers on the right section. The dotted red line separates the clusters corresponding to either CD56^{br} (top) and CD56^{dim} NK cells (bottom). b-c, Relative frequency changes of all identified 1469 unstimulated CD56^{br} (b) and CD56^{dim} (c) NK cell clusters on Day 55 compared to the baseline pre-1470 1471 treatment levels. d, UMAP plot depicts the clustering of *in vitro* stimulated CD56⁺ NK cells. e-f Relative

- 1472 frequency changes of all identified clusters of cells sorted from either the $CD56^{br}(e)$ or $CD56^{dim}(f)$ NK
- 1473 cell gates following *in vitro* stimulation on Day 27 compared to the baseline pre-treatment (Day 0) levels.



Supplementary Figure 14. Induction of the anti-inflammatory gene expression signature at Day 55 is IL-2 dose-dependent and is detected in all T and NK cell populations

a, Volcano plots depicting gene expression changes between Day 0 and Day 55 for the five assessed
immune populations, for unstimulated (left panels) and stimulated (right panels) cells. Significantly
differentially expressed genes are coloured in red (upregulated genes) or blue (downregulated genes).
The top five up- and downregulated genes (as defined by fold change) are labelled on each panel. b,
Principal component analysis (PCA) correlating gene expression changes with dose levels. PCA was
performed on log₂ fold-change values of Day 55 signature genes on Day 27 in CD8⁺ T cells. Each dot
represents a participant, with colours indicating IL-2 dose levels. Vectors representing the gene loading

1485 scores of PC1 and PC2 are shown on the right panel, with genes up- and downregulated on Day 55

1486 shown in red and blue, respectively. c, Day 55 signature scores by participant for each time point. Each

- 1487 participant is represented by a different colour. d, Day 55 signature scores plotted against IL-2 dose. The
- 1488 average value of the Day 55 signature score in the five cell types is shown for each participant.





1492 Supplementary Figure 15. Expression of anti-inflammatory gene expression in COVID-19 patients

a, Day 55 signature scores plotted against the time since COVID-19 symptoms in the COMBAT cohort in NK cells, B cells and mononuclear phagocytes (MNP). **b**, Day 55 signature scores plotted against the time since COVID-19 symptoms in the INCOV cohort in CD4⁺ T cells, CD8⁺ T cells, NK cells and

- 1496 monocytes. In **a** and **b**, each dot represents a pseudo-bulk sample from a certain participant and time
- 1497 point. Up to three longitudinal samples may originate from the same participant. COVID-19 patients
- 1498 were stratified according to their maximum disease severity. Dashed black lines represent smooth curves
- 1499 fitted by locally weighted scatterplot smoothing (LOWESS).
- 1500

Supplementary Information

Supplementary Table 1. Baseline characteristics of study participants

Supplementary Table 2. Targeted mRNA, protein (AbSeq) and immunostaining panels used in this study

Supplementary Table 3. Characteristics of COMBAT study participants with single-cell data available

Supplementary Data 1. Summary of the cluster-specific RNA and AbSeq markers used for cell type annotation

Supplementary Data 2. Differential expression between Day 0 and Day 27 or Day 55 analysed using DESeq2